Christina Yau
Christina Yau
1Department of Surgery (C Yau PhD, M Osdoit MD, M van der Noordaa MD, S Shad BS, J Wei BS, Prof L J Esserman MD), Department of Epidemiology and Biostatistics (Prof M-O Kim PhD), and Department of Laboratory Medicine (Prof L J van ‘t Veer PhD), University of California, San Francisco, San Francisco, CA, USA; Department of Surgery (M Osdoit, Prof F Reyal MD), Department of Tumor Biology (D de Croze MD, M Laé MD), and Department of Medical Oncology (A-S Hamy MD), Institut Curie, Paris, France; Department of Pathology, Université de Rouen Normandie, Rouen, France (M Laé); Department of Medical Oncology (Prof G S Sonke MD, T G Steenbruggen MD) and Department of Pathology (M van Seijen MD, Prof J Wesseling MD), Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Prof M Martín MD, M del Monte-Millán BSc, S López-Tarruella MD); Department of Surgery (Prof J C Boughey MD), Department of Oncology (Prof M P Goetz MD), and Department of Health Sciences Research (T Hoskin MS), Mayo Clinic, Rochester, MN, USA; Department of Pathology and Translational Molecular Pathology (R Gould BSc, Prof W F Symmans MBChB) and Department of Breast Medical Oncology (Prof V Valero MD), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA (Prof S B Edge MD); Department of Oncology (J E Abraham PhD, Prof C Caldas MD, Prof H Earl MBBS, S-J Sammut MD) and Department of Histopathology (E Provenzano MBBS), University of Cambridge, Cambridge, UK; Diagnostic Development Program, Ontario Institute for Cancer Research, Toronto, Canada (Prof J M S Bartlett PhD); Deanery of Molecular, Genetic and Population Health Sciences, Edinburgh Cancer Research Centre, Edinburgh, UK (Prof J M S Bartlett); Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada (Prof J M S Bartlett); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (Prof J Dunn PhD, L Hiller PhD); Department of Oncology (Prof L Hayward MRCP, Prof D Cameron MD, P Hall PhD) and Department of Pathology (J S Thomas MBBS, A Graham MBChB, L Mackintosh MBChB), Western General Hospital, Edinburgh, UK; Department of Pathology and Laboratory Medicine (Prof F Fan MD, Prof A K Godwin PhD) and Department of Medical Oncology (K Schwensen BS, Prof P Sharma MD), University of Kansas Medical Center, Kansas City, KS, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Prof A M DeMichele MD); Department of Pathology (K Cole MD) and Department of Medical Oncology (Prof L Pusztai MD), Yale University, New Haven, CT, USA
1,*,
Marie Osdoit
Marie Osdoit
1Department of Surgery (C Yau PhD, M Osdoit MD, M van der Noordaa MD, S Shad BS, J Wei BS, Prof L J Esserman MD), Department of Epidemiology and Biostatistics (Prof M-O Kim PhD), and Department of Laboratory Medicine (Prof L J van ‘t Veer PhD), University of California, San Francisco, San Francisco, CA, USA; Department of Surgery (M Osdoit, Prof F Reyal MD), Department of Tumor Biology (D de Croze MD, M Laé MD), and Department of Medical Oncology (A-S Hamy MD), Institut Curie, Paris, France; Department of Pathology, Université de Rouen Normandie, Rouen, France (M Laé); Department of Medical Oncology (Prof G S Sonke MD, T G Steenbruggen MD) and Department of Pathology (M van Seijen MD, Prof J Wesseling MD), Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Prof M Martín MD, M del Monte-Millán BSc, S López-Tarruella MD); Department of Surgery (Prof J C Boughey MD), Department of Oncology (Prof M P Goetz MD), and Department of Health Sciences Research (T Hoskin MS), Mayo Clinic, Rochester, MN, USA; Department of Pathology and Translational Molecular Pathology (R Gould BSc, Prof W F Symmans MBChB) and Department of Breast Medical Oncology (Prof V Valero MD), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA (Prof S B Edge MD); Department of Oncology (J E Abraham PhD, Prof C Caldas MD, Prof H Earl MBBS, S-J Sammut MD) and Department of Histopathology (E Provenzano MBBS), University of Cambridge, Cambridge, UK; Diagnostic Development Program, Ontario Institute for Cancer Research, Toronto, Canada (Prof J M S Bartlett PhD); Deanery of Molecular, Genetic and Population Health Sciences, Edinburgh Cancer Research Centre, Edinburgh, UK (Prof J M S Bartlett); Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada (Prof J M S Bartlett); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (Prof J Dunn PhD, L Hiller PhD); Department of Oncology (Prof L Hayward MRCP, Prof D Cameron MD, P Hall PhD) and Department of Pathology (J S Thomas MBBS, A Graham MBChB, L Mackintosh MBChB), Western General Hospital, Edinburgh, UK; Department of Pathology and Laboratory Medicine (Prof F Fan MD, Prof A K Godwin PhD) and Department of Medical Oncology (K Schwensen BS, Prof P Sharma MD), University of Kansas Medical Center, Kansas City, KS, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Prof A M DeMichele MD); Department of Pathology (K Cole MD) and Department of Medical Oncology (Prof L Pusztai MD), Yale University, New Haven, CT, USA
1,*,
Marieke van der Noordaa
Marieke van der Noordaa
1Department of Surgery (C Yau PhD, M Osdoit MD, M van der Noordaa MD, S Shad BS, J Wei BS, Prof L J Esserman MD), Department of Epidemiology and Biostatistics (Prof M-O Kim PhD), and Department of Laboratory Medicine (Prof L J van ‘t Veer PhD), University of California, San Francisco, San Francisco, CA, USA; Department of Surgery (M Osdoit, Prof F Reyal MD), Department of Tumor Biology (D de Croze MD, M Laé MD), and Department of Medical Oncology (A-S Hamy MD), Institut Curie, Paris, France; Department of Pathology, Université de Rouen Normandie, Rouen, France (M Laé); Department of Medical Oncology (Prof G S Sonke MD, T G Steenbruggen MD) and Department of Pathology (M van Seijen MD, Prof J Wesseling MD), Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Prof M Martín MD, M del Monte-Millán BSc, S López-Tarruella MD); Department of Surgery (Prof J C Boughey MD), Department of Oncology (Prof M P Goetz MD), and Department of Health Sciences Research (T Hoskin MS), Mayo Clinic, Rochester, MN, USA; Department of Pathology and Translational Molecular Pathology (R Gould BSc, Prof W F Symmans MBChB) and Department of Breast Medical Oncology (Prof V Valero MD), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA (Prof S B Edge MD); Department of Oncology (J E Abraham PhD, Prof C Caldas MD, Prof H Earl MBBS, S-J Sammut MD) and Department of Histopathology (E Provenzano MBBS), University of Cambridge, Cambridge, UK; Diagnostic Development Program, Ontario Institute for Cancer Research, Toronto, Canada (Prof J M S Bartlett PhD); Deanery of Molecular, Genetic and Population Health Sciences, Edinburgh Cancer Research Centre, Edinburgh, UK (Prof J M S Bartlett); Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada (Prof J M S Bartlett); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (Prof J Dunn PhD, L Hiller PhD); Department of Oncology (Prof L Hayward MRCP, Prof D Cameron MD, P Hall PhD) and Department of Pathology (J S Thomas MBBS, A Graham MBChB, L Mackintosh MBChB), Western General Hospital, Edinburgh, UK; Department of Pathology and Laboratory Medicine (Prof F Fan MD, Prof A K Godwin PhD) and Department of Medical Oncology (K Schwensen BS, Prof P Sharma MD), University of Kansas Medical Center, Kansas City, KS, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Prof A M DeMichele MD); Department of Pathology (K Cole MD) and Department of Medical Oncology (Prof L Pusztai MD), Yale University, New Haven, CT, USA
1,
Sonal Shad
Sonal Shad
1Department of Surgery (C Yau PhD, M Osdoit MD, M van der Noordaa MD, S Shad BS, J Wei BS, Prof L J Esserman MD), Department of Epidemiology and Biostatistics (Prof M-O Kim PhD), and Department of Laboratory Medicine (Prof L J van ‘t Veer PhD), University of California, San Francisco, San Francisco, CA, USA; Department of Surgery (M Osdoit, Prof F Reyal MD), Department of Tumor Biology (D de Croze MD, M Laé MD), and Department of Medical Oncology (A-S Hamy MD), Institut Curie, Paris, France; Department of Pathology, Université de Rouen Normandie, Rouen, France (M Laé); Department of Medical Oncology (Prof G S Sonke MD, T G Steenbruggen MD) and Department of Pathology (M van Seijen MD, Prof J Wesseling MD), Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Prof M Martín MD, M del Monte-Millán BSc, S López-Tarruella MD); Department of Surgery (Prof J C Boughey MD), Department of Oncology (Prof M P Goetz MD), and Department of Health Sciences Research (T Hoskin MS), Mayo Clinic, Rochester, MN, USA; Department of Pathology and Translational Molecular Pathology (R Gould BSc, Prof W F Symmans MBChB) and Department of Breast Medical Oncology (Prof V Valero MD), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA (Prof S B Edge MD); Department of Oncology (J E Abraham PhD, Prof C Caldas MD, Prof H Earl MBBS, S-J Sammut MD) and Department of Histopathology (E Provenzano MBBS), University of Cambridge, Cambridge, UK; Diagnostic Development Program, Ontario Institute for Cancer Research, Toronto, Canada (Prof J M S Bartlett PhD); Deanery of Molecular, Genetic and Population Health Sciences, Edinburgh Cancer Research Centre, Edinburgh, UK (Prof J M S Bartlett); Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada (Prof J M S Bartlett); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (Prof J Dunn PhD, L Hiller PhD); Department of Oncology (Prof L Hayward MRCP, Prof D Cameron MD, P Hall PhD) and Department of Pathology (J S Thomas MBBS, A Graham MBChB, L Mackintosh MBChB), Western General Hospital, Edinburgh, UK; Department of Pathology and Laboratory Medicine (Prof F Fan MD, Prof A K Godwin PhD) and Department of Medical Oncology (K Schwensen BS, Prof P Sharma MD), University of Kansas Medical Center, Kansas City, KS, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Prof A M DeMichele MD); Department of Pathology (K Cole MD) and Department of Medical Oncology (Prof L Pusztai MD), Yale University, New Haven, CT, USA
1,
Jane Wei
Jane Wei
1Department of Surgery (C Yau PhD, M Osdoit MD, M van der Noordaa MD, S Shad BS, J Wei BS, Prof L J Esserman MD), Department of Epidemiology and Biostatistics (Prof M-O Kim PhD), and Department of Laboratory Medicine (Prof L J van ‘t Veer PhD), University of California, San Francisco, San Francisco, CA, USA; Department of Surgery (M Osdoit, Prof F Reyal MD), Department of Tumor Biology (D de Croze MD, M Laé MD), and Department of Medical Oncology (A-S Hamy MD), Institut Curie, Paris, France; Department of Pathology, Université de Rouen Normandie, Rouen, France (M Laé); Department of Medical Oncology (Prof G S Sonke MD, T G Steenbruggen MD) and Department of Pathology (M van Seijen MD, Prof J Wesseling MD), Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Prof M Martín MD, M del Monte-Millán BSc, S López-Tarruella MD); Department of Surgery (Prof J C Boughey MD), Department of Oncology (Prof M P Goetz MD), and Department of Health Sciences Research (T Hoskin MS), Mayo Clinic, Rochester, MN, USA; Department of Pathology and Translational Molecular Pathology (R Gould BSc, Prof W F Symmans MBChB) and Department of Breast Medical Oncology (Prof V Valero MD), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA (Prof S B Edge MD); Department of Oncology (J E Abraham PhD, Prof C Caldas MD, Prof H Earl MBBS, S-J Sammut MD) and Department of Histopathology (E Provenzano MBBS), University of Cambridge, Cambridge, UK; Diagnostic Development Program, Ontario Institute for Cancer Research, Toronto, Canada (Prof J M S Bartlett PhD); Deanery of Molecular, Genetic and Population Health Sciences, Edinburgh Cancer Research Centre, Edinburgh, UK (Prof J M S Bartlett); Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada (Prof J M S Bartlett); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (Prof J Dunn PhD, L Hiller PhD); Department of Oncology (Prof L Hayward MRCP, Prof D Cameron MD, P Hall PhD) and Department of Pathology (J S Thomas MBBS, A Graham MBChB, L Mackintosh MBChB), Western General Hospital, Edinburgh, UK; Department of Pathology and Laboratory Medicine (Prof F Fan MD, Prof A K Godwin PhD) and Department of Medical Oncology (K Schwensen BS, Prof P Sharma MD), University of Kansas Medical Center, Kansas City, KS, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Prof A M DeMichele MD); Department of Pathology (K Cole MD) and Department of Medical Oncology (Prof L Pusztai MD), Yale University, New Haven, CT, USA
1,
Diane de Croze
Diane de Croze
1Department of Surgery (C Yau PhD, M Osdoit MD, M van der Noordaa MD, S Shad BS, J Wei BS, Prof L J Esserman MD), Department of Epidemiology and Biostatistics (Prof M-O Kim PhD), and Department of Laboratory Medicine (Prof L J van ‘t Veer PhD), University of California, San Francisco, San Francisco, CA, USA; Department of Surgery (M Osdoit, Prof F Reyal MD), Department of Tumor Biology (D de Croze MD, M Laé MD), and Department of Medical Oncology (A-S Hamy MD), Institut Curie, Paris, France; Department of Pathology, Université de Rouen Normandie, Rouen, France (M Laé); Department of Medical Oncology (Prof G S Sonke MD, T G Steenbruggen MD) and Department of Pathology (M van Seijen MD, Prof J Wesseling MD), Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Prof M Martín MD, M del Monte-Millán BSc, S López-Tarruella MD); Department of Surgery (Prof J C Boughey MD), Department of Oncology (Prof M P Goetz MD), and Department of Health Sciences Research (T Hoskin MS), Mayo Clinic, Rochester, MN, USA; Department of Pathology and Translational Molecular Pathology (R Gould BSc, Prof W F Symmans MBChB) and Department of Breast Medical Oncology (Prof V Valero MD), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA (Prof S B Edge MD); Department of Oncology (J E Abraham PhD, Prof C Caldas MD, Prof H Earl MBBS, S-J Sammut MD) and Department of Histopathology (E Provenzano MBBS), University of Cambridge, Cambridge, UK; Diagnostic Development Program, Ontario Institute for Cancer Research, Toronto, Canada (Prof J M S Bartlett PhD); Deanery of Molecular, Genetic and Population Health Sciences, Edinburgh Cancer Research Centre, Edinburgh, UK (Prof J M S Bartlett); Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada (Prof J M S Bartlett); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (Prof J Dunn PhD, L Hiller PhD); Department of Oncology (Prof L Hayward MRCP, Prof D Cameron MD, P Hall PhD) and Department of Pathology (J S Thomas MBBS, A Graham MBChB, L Mackintosh MBChB), Western General Hospital, Edinburgh, UK; Department of Pathology and Laboratory Medicine (Prof F Fan MD, Prof A K Godwin PhD) and Department of Medical Oncology (K Schwensen BS, Prof P Sharma MD), University of Kansas Medical Center, Kansas City, KS, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Prof A M DeMichele MD); Department of Pathology (K Cole MD) and Department of Medical Oncology (Prof L Pusztai MD), Yale University, New Haven, CT, USA
1,
Anne-Sophie Hamy
Anne-Sophie Hamy
1Department of Surgery (C Yau PhD, M Osdoit MD, M van der Noordaa MD, S Shad BS, J Wei BS, Prof L J Esserman MD), Department of Epidemiology and Biostatistics (Prof M-O Kim PhD), and Department of Laboratory Medicine (Prof L J van ‘t Veer PhD), University of California, San Francisco, San Francisco, CA, USA; Department of Surgery (M Osdoit, Prof F Reyal MD), Department of Tumor Biology (D de Croze MD, M Laé MD), and Department of Medical Oncology (A-S Hamy MD), Institut Curie, Paris, France; Department of Pathology, Université de Rouen Normandie, Rouen, France (M Laé); Department of Medical Oncology (Prof G S Sonke MD, T G Steenbruggen MD) and Department of Pathology (M van Seijen MD, Prof J Wesseling MD), Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Prof M Martín MD, M del Monte-Millán BSc, S López-Tarruella MD); Department of Surgery (Prof J C Boughey MD), Department of Oncology (Prof M P Goetz MD), and Department of Health Sciences Research (T Hoskin MS), Mayo Clinic, Rochester, MN, USA; Department of Pathology and Translational Molecular Pathology (R Gould BSc, Prof W F Symmans MBChB) and Department of Breast Medical Oncology (Prof V Valero MD), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA (Prof S B Edge MD); Department of Oncology (J E Abraham PhD, Prof C Caldas MD, Prof H Earl MBBS, S-J Sammut MD) and Department of Histopathology (E Provenzano MBBS), University of Cambridge, Cambridge, UK; Diagnostic Development Program, Ontario Institute for Cancer Research, Toronto, Canada (Prof J M S Bartlett PhD); Deanery of Molecular, Genetic and Population Health Sciences, Edinburgh Cancer Research Centre, Edinburgh, UK (Prof J M S Bartlett); Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada (Prof J M S Bartlett); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (Prof J Dunn PhD, L Hiller PhD); Department of Oncology (Prof L Hayward MRCP, Prof D Cameron MD, P Hall PhD) and Department of Pathology (J S Thomas MBBS, A Graham MBChB, L Mackintosh MBChB), Western General Hospital, Edinburgh, UK; Department of Pathology and Laboratory Medicine (Prof F Fan MD, Prof A K Godwin PhD) and Department of Medical Oncology (K Schwensen BS, Prof P Sharma MD), University of Kansas Medical Center, Kansas City, KS, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Prof A M DeMichele MD); Department of Pathology (K Cole MD) and Department of Medical Oncology (Prof L Pusztai MD), Yale University, New Haven, CT, USA
1,
Marick Laé
Marick Laé
1Department of Surgery (C Yau PhD, M Osdoit MD, M van der Noordaa MD, S Shad BS, J Wei BS, Prof L J Esserman MD), Department of Epidemiology and Biostatistics (Prof M-O Kim PhD), and Department of Laboratory Medicine (Prof L J van ‘t Veer PhD), University of California, San Francisco, San Francisco, CA, USA; Department of Surgery (M Osdoit, Prof F Reyal MD), Department of Tumor Biology (D de Croze MD, M Laé MD), and Department of Medical Oncology (A-S Hamy MD), Institut Curie, Paris, France; Department of Pathology, Université de Rouen Normandie, Rouen, France (M Laé); Department of Medical Oncology (Prof G S Sonke MD, T G Steenbruggen MD) and Department of Pathology (M van Seijen MD, Prof J Wesseling MD), Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Prof M Martín MD, M del Monte-Millán BSc, S López-Tarruella MD); Department of Surgery (Prof J C Boughey MD), Department of Oncology (Prof M P Goetz MD), and Department of Health Sciences Research (T Hoskin MS), Mayo Clinic, Rochester, MN, USA; Department of Pathology and Translational Molecular Pathology (R Gould BSc, Prof W F Symmans MBChB) and Department of Breast Medical Oncology (Prof V Valero MD), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA (Prof S B Edge MD); Department of Oncology (J E Abraham PhD, Prof C Caldas MD, Prof H Earl MBBS, S-J Sammut MD) and Department of Histopathology (E Provenzano MBBS), University of Cambridge, Cambridge, UK; Diagnostic Development Program, Ontario Institute for Cancer Research, Toronto, Canada (Prof J M S Bartlett PhD); Deanery of Molecular, Genetic and Population Health Sciences, Edinburgh Cancer Research Centre, Edinburgh, UK (Prof J M S Bartlett); Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada (Prof J M S Bartlett); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (Prof J Dunn PhD, L Hiller PhD); Department of Oncology (Prof L Hayward MRCP, Prof D Cameron MD, P Hall PhD) and Department of Pathology (J S Thomas MBBS, A Graham MBChB, L Mackintosh MBChB), Western General Hospital, Edinburgh, UK; Department of Pathology and Laboratory Medicine (Prof F Fan MD, Prof A K Godwin PhD) and Department of Medical Oncology (K Schwensen BS, Prof P Sharma MD), University of Kansas Medical Center, Kansas City, KS, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Prof A M DeMichele MD); Department of Pathology (K Cole MD) and Department of Medical Oncology (Prof L Pusztai MD), Yale University, New Haven, CT, USA
1,
Fabien Reyal
Fabien Reyal
1Department of Surgery (C Yau PhD, M Osdoit MD, M van der Noordaa MD, S Shad BS, J Wei BS, Prof L J Esserman MD), Department of Epidemiology and Biostatistics (Prof M-O Kim PhD), and Department of Laboratory Medicine (Prof L J van ‘t Veer PhD), University of California, San Francisco, San Francisco, CA, USA; Department of Surgery (M Osdoit, Prof F Reyal MD), Department of Tumor Biology (D de Croze MD, M Laé MD), and Department of Medical Oncology (A-S Hamy MD), Institut Curie, Paris, France; Department of Pathology, Université de Rouen Normandie, Rouen, France (M Laé); Department of Medical Oncology (Prof G S Sonke MD, T G Steenbruggen MD) and Department of Pathology (M van Seijen MD, Prof J Wesseling MD), Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Prof M Martín MD, M del Monte-Millán BSc, S López-Tarruella MD); Department of Surgery (Prof J C Boughey MD), Department of Oncology (Prof M P Goetz MD), and Department of Health Sciences Research (T Hoskin MS), Mayo Clinic, Rochester, MN, USA; Department of Pathology and Translational Molecular Pathology (R Gould BSc, Prof W F Symmans MBChB) and Department of Breast Medical Oncology (Prof V Valero MD), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA (Prof S B Edge MD); Department of Oncology (J E Abraham PhD, Prof C Caldas MD, Prof H Earl MBBS, S-J Sammut MD) and Department of Histopathology (E Provenzano MBBS), University of Cambridge, Cambridge, UK; Diagnostic Development Program, Ontario Institute for Cancer Research, Toronto, Canada (Prof J M S Bartlett PhD); Deanery of Molecular, Genetic and Population Health Sciences, Edinburgh Cancer Research Centre, Edinburgh, UK (Prof J M S Bartlett); Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada (Prof J M S Bartlett); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (Prof J Dunn PhD, L Hiller PhD); Department of Oncology (Prof L Hayward MRCP, Prof D Cameron MD, P Hall PhD) and Department of Pathology (J S Thomas MBBS, A Graham MBChB, L Mackintosh MBChB), Western General Hospital, Edinburgh, UK; Department of Pathology and Laboratory Medicine (Prof F Fan MD, Prof A K Godwin PhD) and Department of Medical Oncology (K Schwensen BS, Prof P Sharma MD), University of Kansas Medical Center, Kansas City, KS, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Prof A M DeMichele MD); Department of Pathology (K Cole MD) and Department of Medical Oncology (Prof L Pusztai MD), Yale University, New Haven, CT, USA
1,
Gabe S Sonke
Gabe S Sonke
1Department of Surgery (C Yau PhD, M Osdoit MD, M van der Noordaa MD, S Shad BS, J Wei BS, Prof L J Esserman MD), Department of Epidemiology and Biostatistics (Prof M-O Kim PhD), and Department of Laboratory Medicine (Prof L J van ‘t Veer PhD), University of California, San Francisco, San Francisco, CA, USA; Department of Surgery (M Osdoit, Prof F Reyal MD), Department of Tumor Biology (D de Croze MD, M Laé MD), and Department of Medical Oncology (A-S Hamy MD), Institut Curie, Paris, France; Department of Pathology, Université de Rouen Normandie, Rouen, France (M Laé); Department of Medical Oncology (Prof G S Sonke MD, T G Steenbruggen MD) and Department of Pathology (M van Seijen MD, Prof J Wesseling MD), Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Prof M Martín MD, M del Monte-Millán BSc, S López-Tarruella MD); Department of Surgery (Prof J C Boughey MD), Department of Oncology (Prof M P Goetz MD), and Department of Health Sciences Research (T Hoskin MS), Mayo Clinic, Rochester, MN, USA; Department of Pathology and Translational Molecular Pathology (R Gould BSc, Prof W F Symmans MBChB) and Department of Breast Medical Oncology (Prof V Valero MD), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA (Prof S B Edge MD); Department of Oncology (J E Abraham PhD, Prof C Caldas MD, Prof H Earl MBBS, S-J Sammut MD) and Department of Histopathology (E Provenzano MBBS), University of Cambridge, Cambridge, UK; Diagnostic Development Program, Ontario Institute for Cancer Research, Toronto, Canada (Prof J M S Bartlett PhD); Deanery of Molecular, Genetic and Population Health Sciences, Edinburgh Cancer Research Centre, Edinburgh, UK (Prof J M S Bartlett); Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada (Prof J M S Bartlett); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (Prof J Dunn PhD, L Hiller PhD); Department of Oncology (Prof L Hayward MRCP, Prof D Cameron MD, P Hall PhD) and Department of Pathology (J S Thomas MBBS, A Graham MBChB, L Mackintosh MBChB), Western General Hospital, Edinburgh, UK; Department of Pathology and Laboratory Medicine (Prof F Fan MD, Prof A K Godwin PhD) and Department of Medical Oncology (K Schwensen BS, Prof P Sharma MD), University of Kansas Medical Center, Kansas City, KS, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Prof A M DeMichele MD); Department of Pathology (K Cole MD) and Department of Medical Oncology (Prof L Pusztai MD), Yale University, New Haven, CT, USA
1,
Tessa G Steenbruggen
Tessa G Steenbruggen
1Department of Surgery (C Yau PhD, M Osdoit MD, M van der Noordaa MD, S Shad BS, J Wei BS, Prof L J Esserman MD), Department of Epidemiology and Biostatistics (Prof M-O Kim PhD), and Department of Laboratory Medicine (Prof L J van ‘t Veer PhD), University of California, San Francisco, San Francisco, CA, USA; Department of Surgery (M Osdoit, Prof F Reyal MD), Department of Tumor Biology (D de Croze MD, M Laé MD), and Department of Medical Oncology (A-S Hamy MD), Institut Curie, Paris, France; Department of Pathology, Université de Rouen Normandie, Rouen, France (M Laé); Department of Medical Oncology (Prof G S Sonke MD, T G Steenbruggen MD) and Department of Pathology (M van Seijen MD, Prof J Wesseling MD), Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Prof M Martín MD, M del Monte-Millán BSc, S López-Tarruella MD); Department of Surgery (Prof J C Boughey MD), Department of Oncology (Prof M P Goetz MD), and Department of Health Sciences Research (T Hoskin MS), Mayo Clinic, Rochester, MN, USA; Department of Pathology and Translational Molecular Pathology (R Gould BSc, Prof W F Symmans MBChB) and Department of Breast Medical Oncology (Prof V Valero MD), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA (Prof S B Edge MD); Department of Oncology (J E Abraham PhD, Prof C Caldas MD, Prof H Earl MBBS, S-J Sammut MD) and Department of Histopathology (E Provenzano MBBS), University of Cambridge, Cambridge, UK; Diagnostic Development Program, Ontario Institute for Cancer Research, Toronto, Canada (Prof J M S Bartlett PhD); Deanery of Molecular, Genetic and Population Health Sciences, Edinburgh Cancer Research Centre, Edinburgh, UK (Prof J M S Bartlett); Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada (Prof J M S Bartlett); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (Prof J Dunn PhD, L Hiller PhD); Department of Oncology (Prof L Hayward MRCP, Prof D Cameron MD, P Hall PhD) and Department of Pathology (J S Thomas MBBS, A Graham MBChB, L Mackintosh MBChB), Western General Hospital, Edinburgh, UK; Department of Pathology and Laboratory Medicine (Prof F Fan MD, Prof A K Godwin PhD) and Department of Medical Oncology (K Schwensen BS, Prof P Sharma MD), University of Kansas Medical Center, Kansas City, KS, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Prof A M DeMichele MD); Department of Pathology (K Cole MD) and Department of Medical Oncology (Prof L Pusztai MD), Yale University, New Haven, CT, USA
1,
Maartje van Seijen
Maartje van Seijen
1Department of Surgery (C Yau PhD, M Osdoit MD, M van der Noordaa MD, S Shad BS, J Wei BS, Prof L J Esserman MD), Department of Epidemiology and Biostatistics (Prof M-O Kim PhD), and Department of Laboratory Medicine (Prof L J van ‘t Veer PhD), University of California, San Francisco, San Francisco, CA, USA; Department of Surgery (M Osdoit, Prof F Reyal MD), Department of Tumor Biology (D de Croze MD, M Laé MD), and Department of Medical Oncology (A-S Hamy MD), Institut Curie, Paris, France; Department of Pathology, Université de Rouen Normandie, Rouen, France (M Laé); Department of Medical Oncology (Prof G S Sonke MD, T G Steenbruggen MD) and Department of Pathology (M van Seijen MD, Prof J Wesseling MD), Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Prof M Martín MD, M del Monte-Millán BSc, S López-Tarruella MD); Department of Surgery (Prof J C Boughey MD), Department of Oncology (Prof M P Goetz MD), and Department of Health Sciences Research (T Hoskin MS), Mayo Clinic, Rochester, MN, USA; Department of Pathology and Translational Molecular Pathology (R Gould BSc, Prof W F Symmans MBChB) and Department of Breast Medical Oncology (Prof V Valero MD), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA (Prof S B Edge MD); Department of Oncology (J E Abraham PhD, Prof C Caldas MD, Prof H Earl MBBS, S-J Sammut MD) and Department of Histopathology (E Provenzano MBBS), University of Cambridge, Cambridge, UK; Diagnostic Development Program, Ontario Institute for Cancer Research, Toronto, Canada (Prof J M S Bartlett PhD); Deanery of Molecular, Genetic and Population Health Sciences, Edinburgh Cancer Research Centre, Edinburgh, UK (Prof J M S Bartlett); Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada (Prof J M S Bartlett); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (Prof J Dunn PhD, L Hiller PhD); Department of Oncology (Prof L Hayward MRCP, Prof D Cameron MD, P Hall PhD) and Department of Pathology (J S Thomas MBBS, A Graham MBChB, L Mackintosh MBChB), Western General Hospital, Edinburgh, UK; Department of Pathology and Laboratory Medicine (Prof F Fan MD, Prof A K Godwin PhD) and Department of Medical Oncology (K Schwensen BS, Prof P Sharma MD), University of Kansas Medical Center, Kansas City, KS, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Prof A M DeMichele MD); Department of Pathology (K Cole MD) and Department of Medical Oncology (Prof L Pusztai MD), Yale University, New Haven, CT, USA
1,
Jelle Wesseling
Jelle Wesseling
1Department of Surgery (C Yau PhD, M Osdoit MD, M van der Noordaa MD, S Shad BS, J Wei BS, Prof L J Esserman MD), Department of Epidemiology and Biostatistics (Prof M-O Kim PhD), and Department of Laboratory Medicine (Prof L J van ‘t Veer PhD), University of California, San Francisco, San Francisco, CA, USA; Department of Surgery (M Osdoit, Prof F Reyal MD), Department of Tumor Biology (D de Croze MD, M Laé MD), and Department of Medical Oncology (A-S Hamy MD), Institut Curie, Paris, France; Department of Pathology, Université de Rouen Normandie, Rouen, France (M Laé); Department of Medical Oncology (Prof G S Sonke MD, T G Steenbruggen MD) and Department of Pathology (M van Seijen MD, Prof J Wesseling MD), Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Prof M Martín MD, M del Monte-Millán BSc, S López-Tarruella MD); Department of Surgery (Prof J C Boughey MD), Department of Oncology (Prof M P Goetz MD), and Department of Health Sciences Research (T Hoskin MS), Mayo Clinic, Rochester, MN, USA; Department of Pathology and Translational Molecular Pathology (R Gould BSc, Prof W F Symmans MBChB) and Department of Breast Medical Oncology (Prof V Valero MD), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA (Prof S B Edge MD); Department of Oncology (J E Abraham PhD, Prof C Caldas MD, Prof H Earl MBBS, S-J Sammut MD) and Department of Histopathology (E Provenzano MBBS), University of Cambridge, Cambridge, UK; Diagnostic Development Program, Ontario Institute for Cancer Research, Toronto, Canada (Prof J M S Bartlett PhD); Deanery of Molecular, Genetic and Population Health Sciences, Edinburgh Cancer Research Centre, Edinburgh, UK (Prof J M S Bartlett); Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada (Prof J M S Bartlett); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (Prof J Dunn PhD, L Hiller PhD); Department of Oncology (Prof L Hayward MRCP, Prof D Cameron MD, P Hall PhD) and Department of Pathology (J S Thomas MBBS, A Graham MBChB, L Mackintosh MBChB), Western General Hospital, Edinburgh, UK; Department of Pathology and Laboratory Medicine (Prof F Fan MD, Prof A K Godwin PhD) and Department of Medical Oncology (K Schwensen BS, Prof P Sharma MD), University of Kansas Medical Center, Kansas City, KS, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Prof A M DeMichele MD); Department of Pathology (K Cole MD) and Department of Medical Oncology (Prof L Pusztai MD), Yale University, New Haven, CT, USA
1,
Miguel Martín
Miguel Martín
1Department of Surgery (C Yau PhD, M Osdoit MD, M van der Noordaa MD, S Shad BS, J Wei BS, Prof L J Esserman MD), Department of Epidemiology and Biostatistics (Prof M-O Kim PhD), and Department of Laboratory Medicine (Prof L J van ‘t Veer PhD), University of California, San Francisco, San Francisco, CA, USA; Department of Surgery (M Osdoit, Prof F Reyal MD), Department of Tumor Biology (D de Croze MD, M Laé MD), and Department of Medical Oncology (A-S Hamy MD), Institut Curie, Paris, France; Department of Pathology, Université de Rouen Normandie, Rouen, France (M Laé); Department of Medical Oncology (Prof G S Sonke MD, T G Steenbruggen MD) and Department of Pathology (M van Seijen MD, Prof J Wesseling MD), Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Prof M Martín MD, M del Monte-Millán BSc, S López-Tarruella MD); Department of Surgery (Prof J C Boughey MD), Department of Oncology (Prof M P Goetz MD), and Department of Health Sciences Research (T Hoskin MS), Mayo Clinic, Rochester, MN, USA; Department of Pathology and Translational Molecular Pathology (R Gould BSc, Prof W F Symmans MBChB) and Department of Breast Medical Oncology (Prof V Valero MD), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA (Prof S B Edge MD); Department of Oncology (J E Abraham PhD, Prof C Caldas MD, Prof H Earl MBBS, S-J Sammut MD) and Department of Histopathology (E Provenzano MBBS), University of Cambridge, Cambridge, UK; Diagnostic Development Program, Ontario Institute for Cancer Research, Toronto, Canada (Prof J M S Bartlett PhD); Deanery of Molecular, Genetic and Population Health Sciences, Edinburgh Cancer Research Centre, Edinburgh, UK (Prof J M S Bartlett); Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada (Prof J M S Bartlett); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (Prof J Dunn PhD, L Hiller PhD); Department of Oncology (Prof L Hayward MRCP, Prof D Cameron MD, P Hall PhD) and Department of Pathology (J S Thomas MBBS, A Graham MBChB, L Mackintosh MBChB), Western General Hospital, Edinburgh, UK; Department of Pathology and Laboratory Medicine (Prof F Fan MD, Prof A K Godwin PhD) and Department of Medical Oncology (K Schwensen BS, Prof P Sharma MD), University of Kansas Medical Center, Kansas City, KS, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Prof A M DeMichele MD); Department of Pathology (K Cole MD) and Department of Medical Oncology (Prof L Pusztai MD), Yale University, New Haven, CT, USA
1,
Maria del Monte-Millán
Maria del Monte-Millán
1Department of Surgery (C Yau PhD, M Osdoit MD, M van der Noordaa MD, S Shad BS, J Wei BS, Prof L J Esserman MD), Department of Epidemiology and Biostatistics (Prof M-O Kim PhD), and Department of Laboratory Medicine (Prof L J van ‘t Veer PhD), University of California, San Francisco, San Francisco, CA, USA; Department of Surgery (M Osdoit, Prof F Reyal MD), Department of Tumor Biology (D de Croze MD, M Laé MD), and Department of Medical Oncology (A-S Hamy MD), Institut Curie, Paris, France; Department of Pathology, Université de Rouen Normandie, Rouen, France (M Laé); Department of Medical Oncology (Prof G S Sonke MD, T G Steenbruggen MD) and Department of Pathology (M van Seijen MD, Prof J Wesseling MD), Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Prof M Martín MD, M del Monte-Millán BSc, S López-Tarruella MD); Department of Surgery (Prof J C Boughey MD), Department of Oncology (Prof M P Goetz MD), and Department of Health Sciences Research (T Hoskin MS), Mayo Clinic, Rochester, MN, USA; Department of Pathology and Translational Molecular Pathology (R Gould BSc, Prof W F Symmans MBChB) and Department of Breast Medical Oncology (Prof V Valero MD), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA (Prof S B Edge MD); Department of Oncology (J E Abraham PhD, Prof C Caldas MD, Prof H Earl MBBS, S-J Sammut MD) and Department of Histopathology (E Provenzano MBBS), University of Cambridge, Cambridge, UK; Diagnostic Development Program, Ontario Institute for Cancer Research, Toronto, Canada (Prof J M S Bartlett PhD); Deanery of Molecular, Genetic and Population Health Sciences, Edinburgh Cancer Research Centre, Edinburgh, UK (Prof J M S Bartlett); Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada (Prof J M S Bartlett); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (Prof J Dunn PhD, L Hiller PhD); Department of Oncology (Prof L Hayward MRCP, Prof D Cameron MD, P Hall PhD) and Department of Pathology (J S Thomas MBBS, A Graham MBChB, L Mackintosh MBChB), Western General Hospital, Edinburgh, UK; Department of Pathology and Laboratory Medicine (Prof F Fan MD, Prof A K Godwin PhD) and Department of Medical Oncology (K Schwensen BS, Prof P Sharma MD), University of Kansas Medical Center, Kansas City, KS, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Prof A M DeMichele MD); Department of Pathology (K Cole MD) and Department of Medical Oncology (Prof L Pusztai MD), Yale University, New Haven, CT, USA
1,
Sara López-Tarruella
Sara López-Tarruella
1Department of Surgery (C Yau PhD, M Osdoit MD, M van der Noordaa MD, S Shad BS, J Wei BS, Prof L J Esserman MD), Department of Epidemiology and Biostatistics (Prof M-O Kim PhD), and Department of Laboratory Medicine (Prof L J van ‘t Veer PhD), University of California, San Francisco, San Francisco, CA, USA; Department of Surgery (M Osdoit, Prof F Reyal MD), Department of Tumor Biology (D de Croze MD, M Laé MD), and Department of Medical Oncology (A-S Hamy MD), Institut Curie, Paris, France; Department of Pathology, Université de Rouen Normandie, Rouen, France (M Laé); Department of Medical Oncology (Prof G S Sonke MD, T G Steenbruggen MD) and Department of Pathology (M van Seijen MD, Prof J Wesseling MD), Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Prof M Martín MD, M del Monte-Millán BSc, S López-Tarruella MD); Department of Surgery (Prof J C Boughey MD), Department of Oncology (Prof M P Goetz MD), and Department of Health Sciences Research (T Hoskin MS), Mayo Clinic, Rochester, MN, USA; Department of Pathology and Translational Molecular Pathology (R Gould BSc, Prof W F Symmans MBChB) and Department of Breast Medical Oncology (Prof V Valero MD), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA (Prof S B Edge MD); Department of Oncology (J E Abraham PhD, Prof C Caldas MD, Prof H Earl MBBS, S-J Sammut MD) and Department of Histopathology (E Provenzano MBBS), University of Cambridge, Cambridge, UK; Diagnostic Development Program, Ontario Institute for Cancer Research, Toronto, Canada (Prof J M S Bartlett PhD); Deanery of Molecular, Genetic and Population Health Sciences, Edinburgh Cancer Research Centre, Edinburgh, UK (Prof J M S Bartlett); Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada (Prof J M S Bartlett); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (Prof J Dunn PhD, L Hiller PhD); Department of Oncology (Prof L Hayward MRCP, Prof D Cameron MD, P Hall PhD) and Department of Pathology (J S Thomas MBBS, A Graham MBChB, L Mackintosh MBChB), Western General Hospital, Edinburgh, UK; Department of Pathology and Laboratory Medicine (Prof F Fan MD, Prof A K Godwin PhD) and Department of Medical Oncology (K Schwensen BS, Prof P Sharma MD), University of Kansas Medical Center, Kansas City, KS, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Prof A M DeMichele MD); Department of Pathology (K Cole MD) and Department of Medical Oncology (Prof L Pusztai MD), Yale University, New Haven, CT, USA
1;
I-SPY 2 Trial Consortium1,
Judy C Boughey
Judy C Boughey
1Department of Surgery (C Yau PhD, M Osdoit MD, M van der Noordaa MD, S Shad BS, J Wei BS, Prof L J Esserman MD), Department of Epidemiology and Biostatistics (Prof M-O Kim PhD), and Department of Laboratory Medicine (Prof L J van ‘t Veer PhD), University of California, San Francisco, San Francisco, CA, USA; Department of Surgery (M Osdoit, Prof F Reyal MD), Department of Tumor Biology (D de Croze MD, M Laé MD), and Department of Medical Oncology (A-S Hamy MD), Institut Curie, Paris, France; Department of Pathology, Université de Rouen Normandie, Rouen, France (M Laé); Department of Medical Oncology (Prof G S Sonke MD, T G Steenbruggen MD) and Department of Pathology (M van Seijen MD, Prof J Wesseling MD), Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Prof M Martín MD, M del Monte-Millán BSc, S López-Tarruella MD); Department of Surgery (Prof J C Boughey MD), Department of Oncology (Prof M P Goetz MD), and Department of Health Sciences Research (T Hoskin MS), Mayo Clinic, Rochester, MN, USA; Department of Pathology and Translational Molecular Pathology (R Gould BSc, Prof W F Symmans MBChB) and Department of Breast Medical Oncology (Prof V Valero MD), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA (Prof S B Edge MD); Department of Oncology (J E Abraham PhD, Prof C Caldas MD, Prof H Earl MBBS, S-J Sammut MD) and Department of Histopathology (E Provenzano MBBS), University of Cambridge, Cambridge, UK; Diagnostic Development Program, Ontario Institute for Cancer Research, Toronto, Canada (Prof J M S Bartlett PhD); Deanery of Molecular, Genetic and Population Health Sciences, Edinburgh Cancer Research Centre, Edinburgh, UK (Prof J M S Bartlett); Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada (Prof J M S Bartlett); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (Prof J Dunn PhD, L Hiller PhD); Department of Oncology (Prof L Hayward MRCP, Prof D Cameron MD, P Hall PhD) and Department of Pathology (J S Thomas MBBS, A Graham MBChB, L Mackintosh MBChB), Western General Hospital, Edinburgh, UK; Department of Pathology and Laboratory Medicine (Prof F Fan MD, Prof A K Godwin PhD) and Department of Medical Oncology (K Schwensen BS, Prof P Sharma MD), University of Kansas Medical Center, Kansas City, KS, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Prof A M DeMichele MD); Department of Pathology (K Cole MD) and Department of Medical Oncology (Prof L Pusztai MD), Yale University, New Haven, CT, USA
1,
Matthew P Goetz
Matthew P Goetz
1Department of Surgery (C Yau PhD, M Osdoit MD, M van der Noordaa MD, S Shad BS, J Wei BS, Prof L J Esserman MD), Department of Epidemiology and Biostatistics (Prof M-O Kim PhD), and Department of Laboratory Medicine (Prof L J van ‘t Veer PhD), University of California, San Francisco, San Francisco, CA, USA; Department of Surgery (M Osdoit, Prof F Reyal MD), Department of Tumor Biology (D de Croze MD, M Laé MD), and Department of Medical Oncology (A-S Hamy MD), Institut Curie, Paris, France; Department of Pathology, Université de Rouen Normandie, Rouen, France (M Laé); Department of Medical Oncology (Prof G S Sonke MD, T G Steenbruggen MD) and Department of Pathology (M van Seijen MD, Prof J Wesseling MD), Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Prof M Martín MD, M del Monte-Millán BSc, S López-Tarruella MD); Department of Surgery (Prof J C Boughey MD), Department of Oncology (Prof M P Goetz MD), and Department of Health Sciences Research (T Hoskin MS), Mayo Clinic, Rochester, MN, USA; Department of Pathology and Translational Molecular Pathology (R Gould BSc, Prof W F Symmans MBChB) and Department of Breast Medical Oncology (Prof V Valero MD), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA (Prof S B Edge MD); Department of Oncology (J E Abraham PhD, Prof C Caldas MD, Prof H Earl MBBS, S-J Sammut MD) and Department of Histopathology (E Provenzano MBBS), University of Cambridge, Cambridge, UK; Diagnostic Development Program, Ontario Institute for Cancer Research, Toronto, Canada (Prof J M S Bartlett PhD); Deanery of Molecular, Genetic and Population Health Sciences, Edinburgh Cancer Research Centre, Edinburgh, UK (Prof J M S Bartlett); Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada (Prof J M S Bartlett); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (Prof J Dunn PhD, L Hiller PhD); Department of Oncology (Prof L Hayward MRCP, Prof D Cameron MD, P Hall PhD) and Department of Pathology (J S Thomas MBBS, A Graham MBChB, L Mackintosh MBChB), Western General Hospital, Edinburgh, UK; Department of Pathology and Laboratory Medicine (Prof F Fan MD, Prof A K Godwin PhD) and Department of Medical Oncology (K Schwensen BS, Prof P Sharma MD), University of Kansas Medical Center, Kansas City, KS, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Prof A M DeMichele MD); Department of Pathology (K Cole MD) and Department of Medical Oncology (Prof L Pusztai MD), Yale University, New Haven, CT, USA
1,
Tanya Hoskin
Tanya Hoskin
1Department of Surgery (C Yau PhD, M Osdoit MD, M van der Noordaa MD, S Shad BS, J Wei BS, Prof L J Esserman MD), Department of Epidemiology and Biostatistics (Prof M-O Kim PhD), and Department of Laboratory Medicine (Prof L J van ‘t Veer PhD), University of California, San Francisco, San Francisco, CA, USA; Department of Surgery (M Osdoit, Prof F Reyal MD), Department of Tumor Biology (D de Croze MD, M Laé MD), and Department of Medical Oncology (A-S Hamy MD), Institut Curie, Paris, France; Department of Pathology, Université de Rouen Normandie, Rouen, France (M Laé); Department of Medical Oncology (Prof G S Sonke MD, T G Steenbruggen MD) and Department of Pathology (M van Seijen MD, Prof J Wesseling MD), Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Prof M Martín MD, M del Monte-Millán BSc, S López-Tarruella MD); Department of Surgery (Prof J C Boughey MD), Department of Oncology (Prof M P Goetz MD), and Department of Health Sciences Research (T Hoskin MS), Mayo Clinic, Rochester, MN, USA; Department of Pathology and Translational Molecular Pathology (R Gould BSc, Prof W F Symmans MBChB) and Department of Breast Medical Oncology (Prof V Valero MD), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA (Prof S B Edge MD); Department of Oncology (J E Abraham PhD, Prof C Caldas MD, Prof H Earl MBBS, S-J Sammut MD) and Department of Histopathology (E Provenzano MBBS), University of Cambridge, Cambridge, UK; Diagnostic Development Program, Ontario Institute for Cancer Research, Toronto, Canada (Prof J M S Bartlett PhD); Deanery of Molecular, Genetic and Population Health Sciences, Edinburgh Cancer Research Centre, Edinburgh, UK (Prof J M S Bartlett); Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada (Prof J M S Bartlett); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (Prof J Dunn PhD, L Hiller PhD); Department of Oncology (Prof L Hayward MRCP, Prof D Cameron MD, P Hall PhD) and Department of Pathology (J S Thomas MBBS, A Graham MBChB, L Mackintosh MBChB), Western General Hospital, Edinburgh, UK; Department of Pathology and Laboratory Medicine (Prof F Fan MD, Prof A K Godwin PhD) and Department of Medical Oncology (K Schwensen BS, Prof P Sharma MD), University of Kansas Medical Center, Kansas City, KS, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Prof A M DeMichele MD); Department of Pathology (K Cole MD) and Department of Medical Oncology (Prof L Pusztai MD), Yale University, New Haven, CT, USA
1,
Rebekah Gould
Rebekah Gould
1Department of Surgery (C Yau PhD, M Osdoit MD, M van der Noordaa MD, S Shad BS, J Wei BS, Prof L J Esserman MD), Department of Epidemiology and Biostatistics (Prof M-O Kim PhD), and Department of Laboratory Medicine (Prof L J van ‘t Veer PhD), University of California, San Francisco, San Francisco, CA, USA; Department of Surgery (M Osdoit, Prof F Reyal MD), Department of Tumor Biology (D de Croze MD, M Laé MD), and Department of Medical Oncology (A-S Hamy MD), Institut Curie, Paris, France; Department of Pathology, Université de Rouen Normandie, Rouen, France (M Laé); Department of Medical Oncology (Prof G S Sonke MD, T G Steenbruggen MD) and Department of Pathology (M van Seijen MD, Prof J Wesseling MD), Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Prof M Martín MD, M del Monte-Millán BSc, S López-Tarruella MD); Department of Surgery (Prof J C Boughey MD), Department of Oncology (Prof M P Goetz MD), and Department of Health Sciences Research (T Hoskin MS), Mayo Clinic, Rochester, MN, USA; Department of Pathology and Translational Molecular Pathology (R Gould BSc, Prof W F Symmans MBChB) and Department of Breast Medical Oncology (Prof V Valero MD), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA (Prof S B Edge MD); Department of Oncology (J E Abraham PhD, Prof C Caldas MD, Prof H Earl MBBS, S-J Sammut MD) and Department of Histopathology (E Provenzano MBBS), University of Cambridge, Cambridge, UK; Diagnostic Development Program, Ontario Institute for Cancer Research, Toronto, Canada (Prof J M S Bartlett PhD); Deanery of Molecular, Genetic and Population Health Sciences, Edinburgh Cancer Research Centre, Edinburgh, UK (Prof J M S Bartlett); Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada (Prof J M S Bartlett); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (Prof J Dunn PhD, L Hiller PhD); Department of Oncology (Prof L Hayward MRCP, Prof D Cameron MD, P Hall PhD) and Department of Pathology (J S Thomas MBBS, A Graham MBChB, L Mackintosh MBChB), Western General Hospital, Edinburgh, UK; Department of Pathology and Laboratory Medicine (Prof F Fan MD, Prof A K Godwin PhD) and Department of Medical Oncology (K Schwensen BS, Prof P Sharma MD), University of Kansas Medical Center, Kansas City, KS, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Prof A M DeMichele MD); Department of Pathology (K Cole MD) and Department of Medical Oncology (Prof L Pusztai MD), Yale University, New Haven, CT, USA
1,
Vicente Valero
Vicente Valero
1Department of Surgery (C Yau PhD, M Osdoit MD, M van der Noordaa MD, S Shad BS, J Wei BS, Prof L J Esserman MD), Department of Epidemiology and Biostatistics (Prof M-O Kim PhD), and Department of Laboratory Medicine (Prof L J van ‘t Veer PhD), University of California, San Francisco, San Francisco, CA, USA; Department of Surgery (M Osdoit, Prof F Reyal MD), Department of Tumor Biology (D de Croze MD, M Laé MD), and Department of Medical Oncology (A-S Hamy MD), Institut Curie, Paris, France; Department of Pathology, Université de Rouen Normandie, Rouen, France (M Laé); Department of Medical Oncology (Prof G S Sonke MD, T G Steenbruggen MD) and Department of Pathology (M van Seijen MD, Prof J Wesseling MD), Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Prof M Martín MD, M del Monte-Millán BSc, S López-Tarruella MD); Department of Surgery (Prof J C Boughey MD), Department of Oncology (Prof M P Goetz MD), and Department of Health Sciences Research (T Hoskin MS), Mayo Clinic, Rochester, MN, USA; Department of Pathology and Translational Molecular Pathology (R Gould BSc, Prof W F Symmans MBChB) and Department of Breast Medical Oncology (Prof V Valero MD), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA (Prof S B Edge MD); Department of Oncology (J E Abraham PhD, Prof C Caldas MD, Prof H Earl MBBS, S-J Sammut MD) and Department of Histopathology (E Provenzano MBBS), University of Cambridge, Cambridge, UK; Diagnostic Development Program, Ontario Institute for Cancer Research, Toronto, Canada (Prof J M S Bartlett PhD); Deanery of Molecular, Genetic and Population Health Sciences, Edinburgh Cancer Research Centre, Edinburgh, UK (Prof J M S Bartlett); Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada (Prof J M S Bartlett); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (Prof J Dunn PhD, L Hiller PhD); Department of Oncology (Prof L Hayward MRCP, Prof D Cameron MD, P Hall PhD) and Department of Pathology (J S Thomas MBBS, A Graham MBChB, L Mackintosh MBChB), Western General Hospital, Edinburgh, UK; Department of Pathology and Laboratory Medicine (Prof F Fan MD, Prof A K Godwin PhD) and Department of Medical Oncology (K Schwensen BS, Prof P Sharma MD), University of Kansas Medical Center, Kansas City, KS, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Prof A M DeMichele MD); Department of Pathology (K Cole MD) and Department of Medical Oncology (Prof L Pusztai MD), Yale University, New Haven, CT, USA
1,
Stephen B Edge
Stephen B Edge
1Department of Surgery (C Yau PhD, M Osdoit MD, M van der Noordaa MD, S Shad BS, J Wei BS, Prof L J Esserman MD), Department of Epidemiology and Biostatistics (Prof M-O Kim PhD), and Department of Laboratory Medicine (Prof L J van ‘t Veer PhD), University of California, San Francisco, San Francisco, CA, USA; Department of Surgery (M Osdoit, Prof F Reyal MD), Department of Tumor Biology (D de Croze MD, M Laé MD), and Department of Medical Oncology (A-S Hamy MD), Institut Curie, Paris, France; Department of Pathology, Université de Rouen Normandie, Rouen, France (M Laé); Department of Medical Oncology (Prof G S Sonke MD, T G Steenbruggen MD) and Department of Pathology (M van Seijen MD, Prof J Wesseling MD), Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Prof M Martín MD, M del Monte-Millán BSc, S López-Tarruella MD); Department of Surgery (Prof J C Boughey MD), Department of Oncology (Prof M P Goetz MD), and Department of Health Sciences Research (T Hoskin MS), Mayo Clinic, Rochester, MN, USA; Department of Pathology and Translational Molecular Pathology (R Gould BSc, Prof W F Symmans MBChB) and Department of Breast Medical Oncology (Prof V Valero MD), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA (Prof S B Edge MD); Department of Oncology (J E Abraham PhD, Prof C Caldas MD, Prof H Earl MBBS, S-J Sammut MD) and Department of Histopathology (E Provenzano MBBS), University of Cambridge, Cambridge, UK; Diagnostic Development Program, Ontario Institute for Cancer Research, Toronto, Canada (Prof J M S Bartlett PhD); Deanery of Molecular, Genetic and Population Health Sciences, Edinburgh Cancer Research Centre, Edinburgh, UK (Prof J M S Bartlett); Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada (Prof J M S Bartlett); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (Prof J Dunn PhD, L Hiller PhD); Department of Oncology (Prof L Hayward MRCP, Prof D Cameron MD, P Hall PhD) and Department of Pathology (J S Thomas MBBS, A Graham MBChB, L Mackintosh MBChB), Western General Hospital, Edinburgh, UK; Department of Pathology and Laboratory Medicine (Prof F Fan MD, Prof A K Godwin PhD) and Department of Medical Oncology (K Schwensen BS, Prof P Sharma MD), University of Kansas Medical Center, Kansas City, KS, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Prof A M DeMichele MD); Department of Pathology (K Cole MD) and Department of Medical Oncology (Prof L Pusztai MD), Yale University, New Haven, CT, USA
1,
Jean E Abraham
Jean E Abraham
1Department of Surgery (C Yau PhD, M Osdoit MD, M van der Noordaa MD, S Shad BS, J Wei BS, Prof L J Esserman MD), Department of Epidemiology and Biostatistics (Prof M-O Kim PhD), and Department of Laboratory Medicine (Prof L J van ‘t Veer PhD), University of California, San Francisco, San Francisco, CA, USA; Department of Surgery (M Osdoit, Prof F Reyal MD), Department of Tumor Biology (D de Croze MD, M Laé MD), and Department of Medical Oncology (A-S Hamy MD), Institut Curie, Paris, France; Department of Pathology, Université de Rouen Normandie, Rouen, France (M Laé); Department of Medical Oncology (Prof G S Sonke MD, T G Steenbruggen MD) and Department of Pathology (M van Seijen MD, Prof J Wesseling MD), Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Prof M Martín MD, M del Monte-Millán BSc, S López-Tarruella MD); Department of Surgery (Prof J C Boughey MD), Department of Oncology (Prof M P Goetz MD), and Department of Health Sciences Research (T Hoskin MS), Mayo Clinic, Rochester, MN, USA; Department of Pathology and Translational Molecular Pathology (R Gould BSc, Prof W F Symmans MBChB) and Department of Breast Medical Oncology (Prof V Valero MD), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA (Prof S B Edge MD); Department of Oncology (J E Abraham PhD, Prof C Caldas MD, Prof H Earl MBBS, S-J Sammut MD) and Department of Histopathology (E Provenzano MBBS), University of Cambridge, Cambridge, UK; Diagnostic Development Program, Ontario Institute for Cancer Research, Toronto, Canada (Prof J M S Bartlett PhD); Deanery of Molecular, Genetic and Population Health Sciences, Edinburgh Cancer Research Centre, Edinburgh, UK (Prof J M S Bartlett); Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada (Prof J M S Bartlett); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (Prof J Dunn PhD, L Hiller PhD); Department of Oncology (Prof L Hayward MRCP, Prof D Cameron MD, P Hall PhD) and Department of Pathology (J S Thomas MBBS, A Graham MBChB, L Mackintosh MBChB), Western General Hospital, Edinburgh, UK; Department of Pathology and Laboratory Medicine (Prof F Fan MD, Prof A K Godwin PhD) and Department of Medical Oncology (K Schwensen BS, Prof P Sharma MD), University of Kansas Medical Center, Kansas City, KS, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Prof A M DeMichele MD); Department of Pathology (K Cole MD) and Department of Medical Oncology (Prof L Pusztai MD), Yale University, New Haven, CT, USA
1,
John M S Bartlett
John M S Bartlett
1Department of Surgery (C Yau PhD, M Osdoit MD, M van der Noordaa MD, S Shad BS, J Wei BS, Prof L J Esserman MD), Department of Epidemiology and Biostatistics (Prof M-O Kim PhD), and Department of Laboratory Medicine (Prof L J van ‘t Veer PhD), University of California, San Francisco, San Francisco, CA, USA; Department of Surgery (M Osdoit, Prof F Reyal MD), Department of Tumor Biology (D de Croze MD, M Laé MD), and Department of Medical Oncology (A-S Hamy MD), Institut Curie, Paris, France; Department of Pathology, Université de Rouen Normandie, Rouen, France (M Laé); Department of Medical Oncology (Prof G S Sonke MD, T G Steenbruggen MD) and Department of Pathology (M van Seijen MD, Prof J Wesseling MD), Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Prof M Martín MD, M del Monte-Millán BSc, S López-Tarruella MD); Department of Surgery (Prof J C Boughey MD), Department of Oncology (Prof M P Goetz MD), and Department of Health Sciences Research (T Hoskin MS), Mayo Clinic, Rochester, MN, USA; Department of Pathology and Translational Molecular Pathology (R Gould BSc, Prof W F Symmans MBChB) and Department of Breast Medical Oncology (Prof V Valero MD), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA (Prof S B Edge MD); Department of Oncology (J E Abraham PhD, Prof C Caldas MD, Prof H Earl MBBS, S-J Sammut MD) and Department of Histopathology (E Provenzano MBBS), University of Cambridge, Cambridge, UK; Diagnostic Development Program, Ontario Institute for Cancer Research, Toronto, Canada (Prof J M S Bartlett PhD); Deanery of Molecular, Genetic and Population Health Sciences, Edinburgh Cancer Research Centre, Edinburgh, UK (Prof J M S Bartlett); Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada (Prof J M S Bartlett); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (Prof J Dunn PhD, L Hiller PhD); Department of Oncology (Prof L Hayward MRCP, Prof D Cameron MD, P Hall PhD) and Department of Pathology (J S Thomas MBBS, A Graham MBChB, L Mackintosh MBChB), Western General Hospital, Edinburgh, UK; Department of Pathology and Laboratory Medicine (Prof F Fan MD, Prof A K Godwin PhD) and Department of Medical Oncology (K Schwensen BS, Prof P Sharma MD), University of Kansas Medical Center, Kansas City, KS, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Prof A M DeMichele MD); Department of Pathology (K Cole MD) and Department of Medical Oncology (Prof L Pusztai MD), Yale University, New Haven, CT, USA
1,
Carlos Caldas
Carlos Caldas
1Department of Surgery (C Yau PhD, M Osdoit MD, M van der Noordaa MD, S Shad BS, J Wei BS, Prof L J Esserman MD), Department of Epidemiology and Biostatistics (Prof M-O Kim PhD), and Department of Laboratory Medicine (Prof L J van ‘t Veer PhD), University of California, San Francisco, San Francisco, CA, USA; Department of Surgery (M Osdoit, Prof F Reyal MD), Department of Tumor Biology (D de Croze MD, M Laé MD), and Department of Medical Oncology (A-S Hamy MD), Institut Curie, Paris, France; Department of Pathology, Université de Rouen Normandie, Rouen, France (M Laé); Department of Medical Oncology (Prof G S Sonke MD, T G Steenbruggen MD) and Department of Pathology (M van Seijen MD, Prof J Wesseling MD), Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Prof M Martín MD, M del Monte-Millán BSc, S López-Tarruella MD); Department of Surgery (Prof J C Boughey MD), Department of Oncology (Prof M P Goetz MD), and Department of Health Sciences Research (T Hoskin MS), Mayo Clinic, Rochester, MN, USA; Department of Pathology and Translational Molecular Pathology (R Gould BSc, Prof W F Symmans MBChB) and Department of Breast Medical Oncology (Prof V Valero MD), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA (Prof S B Edge MD); Department of Oncology (J E Abraham PhD, Prof C Caldas MD, Prof H Earl MBBS, S-J Sammut MD) and Department of Histopathology (E Provenzano MBBS), University of Cambridge, Cambridge, UK; Diagnostic Development Program, Ontario Institute for Cancer Research, Toronto, Canada (Prof J M S Bartlett PhD); Deanery of Molecular, Genetic and Population Health Sciences, Edinburgh Cancer Research Centre, Edinburgh, UK (Prof J M S Bartlett); Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada (Prof J M S Bartlett); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (Prof J Dunn PhD, L Hiller PhD); Department of Oncology (Prof L Hayward MRCP, Prof D Cameron MD, P Hall PhD) and Department of Pathology (J S Thomas MBBS, A Graham MBChB, L Mackintosh MBChB), Western General Hospital, Edinburgh, UK; Department of Pathology and Laboratory Medicine (Prof F Fan MD, Prof A K Godwin PhD) and Department of Medical Oncology (K Schwensen BS, Prof P Sharma MD), University of Kansas Medical Center, Kansas City, KS, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Prof A M DeMichele MD); Department of Pathology (K Cole MD) and Department of Medical Oncology (Prof L Pusztai MD), Yale University, New Haven, CT, USA
1,
Janet Dunn
Janet Dunn
1Department of Surgery (C Yau PhD, M Osdoit MD, M van der Noordaa MD, S Shad BS, J Wei BS, Prof L J Esserman MD), Department of Epidemiology and Biostatistics (Prof M-O Kim PhD), and Department of Laboratory Medicine (Prof L J van ‘t Veer PhD), University of California, San Francisco, San Francisco, CA, USA; Department of Surgery (M Osdoit, Prof F Reyal MD), Department of Tumor Biology (D de Croze MD, M Laé MD), and Department of Medical Oncology (A-S Hamy MD), Institut Curie, Paris, France; Department of Pathology, Université de Rouen Normandie, Rouen, France (M Laé); Department of Medical Oncology (Prof G S Sonke MD, T G Steenbruggen MD) and Department of Pathology (M van Seijen MD, Prof J Wesseling MD), Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Prof M Martín MD, M del Monte-Millán BSc, S López-Tarruella MD); Department of Surgery (Prof J C Boughey MD), Department of Oncology (Prof M P Goetz MD), and Department of Health Sciences Research (T Hoskin MS), Mayo Clinic, Rochester, MN, USA; Department of Pathology and Translational Molecular Pathology (R Gould BSc, Prof W F Symmans MBChB) and Department of Breast Medical Oncology (Prof V Valero MD), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA (Prof S B Edge MD); Department of Oncology (J E Abraham PhD, Prof C Caldas MD, Prof H Earl MBBS, S-J Sammut MD) and Department of Histopathology (E Provenzano MBBS), University of Cambridge, Cambridge, UK; Diagnostic Development Program, Ontario Institute for Cancer Research, Toronto, Canada (Prof J M S Bartlett PhD); Deanery of Molecular, Genetic and Population Health Sciences, Edinburgh Cancer Research Centre, Edinburgh, UK (Prof J M S Bartlett); Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada (Prof J M S Bartlett); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (Prof J Dunn PhD, L Hiller PhD); Department of Oncology (Prof L Hayward MRCP, Prof D Cameron MD, P Hall PhD) and Department of Pathology (J S Thomas MBBS, A Graham MBChB, L Mackintosh MBChB), Western General Hospital, Edinburgh, UK; Department of Pathology and Laboratory Medicine (Prof F Fan MD, Prof A K Godwin PhD) and Department of Medical Oncology (K Schwensen BS, Prof P Sharma MD), University of Kansas Medical Center, Kansas City, KS, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Prof A M DeMichele MD); Department of Pathology (K Cole MD) and Department of Medical Oncology (Prof L Pusztai MD), Yale University, New Haven, CT, USA
1,
Helena Earl
Helena Earl
1Department of Surgery (C Yau PhD, M Osdoit MD, M van der Noordaa MD, S Shad BS, J Wei BS, Prof L J Esserman MD), Department of Epidemiology and Biostatistics (Prof M-O Kim PhD), and Department of Laboratory Medicine (Prof L J van ‘t Veer PhD), University of California, San Francisco, San Francisco, CA, USA; Department of Surgery (M Osdoit, Prof F Reyal MD), Department of Tumor Biology (D de Croze MD, M Laé MD), and Department of Medical Oncology (A-S Hamy MD), Institut Curie, Paris, France; Department of Pathology, Université de Rouen Normandie, Rouen, France (M Laé); Department of Medical Oncology (Prof G S Sonke MD, T G Steenbruggen MD) and Department of Pathology (M van Seijen MD, Prof J Wesseling MD), Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Prof M Martín MD, M del Monte-Millán BSc, S López-Tarruella MD); Department of Surgery (Prof J C Boughey MD), Department of Oncology (Prof M P Goetz MD), and Department of Health Sciences Research (T Hoskin MS), Mayo Clinic, Rochester, MN, USA; Department of Pathology and Translational Molecular Pathology (R Gould BSc, Prof W F Symmans MBChB) and Department of Breast Medical Oncology (Prof V Valero MD), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA (Prof S B Edge MD); Department of Oncology (J E Abraham PhD, Prof C Caldas MD, Prof H Earl MBBS, S-J Sammut MD) and Department of Histopathology (E Provenzano MBBS), University of Cambridge, Cambridge, UK; Diagnostic Development Program, Ontario Institute for Cancer Research, Toronto, Canada (Prof J M S Bartlett PhD); Deanery of Molecular, Genetic and Population Health Sciences, Edinburgh Cancer Research Centre, Edinburgh, UK (Prof J M S Bartlett); Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada (Prof J M S Bartlett); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (Prof J Dunn PhD, L Hiller PhD); Department of Oncology (Prof L Hayward MRCP, Prof D Cameron MD, P Hall PhD) and Department of Pathology (J S Thomas MBBS, A Graham MBChB, L Mackintosh MBChB), Western General Hospital, Edinburgh, UK; Department of Pathology and Laboratory Medicine (Prof F Fan MD, Prof A K Godwin PhD) and Department of Medical Oncology (K Schwensen BS, Prof P Sharma MD), University of Kansas Medical Center, Kansas City, KS, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Prof A M DeMichele MD); Department of Pathology (K Cole MD) and Department of Medical Oncology (Prof L Pusztai MD), Yale University, New Haven, CT, USA
1,
Larry Hayward
Larry Hayward
1Department of Surgery (C Yau PhD, M Osdoit MD, M van der Noordaa MD, S Shad BS, J Wei BS, Prof L J Esserman MD), Department of Epidemiology and Biostatistics (Prof M-O Kim PhD), and Department of Laboratory Medicine (Prof L J van ‘t Veer PhD), University of California, San Francisco, San Francisco, CA, USA; Department of Surgery (M Osdoit, Prof F Reyal MD), Department of Tumor Biology (D de Croze MD, M Laé MD), and Department of Medical Oncology (A-S Hamy MD), Institut Curie, Paris, France; Department of Pathology, Université de Rouen Normandie, Rouen, France (M Laé); Department of Medical Oncology (Prof G S Sonke MD, T G Steenbruggen MD) and Department of Pathology (M van Seijen MD, Prof J Wesseling MD), Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Prof M Martín MD, M del Monte-Millán BSc, S López-Tarruella MD); Department of Surgery (Prof J C Boughey MD), Department of Oncology (Prof M P Goetz MD), and Department of Health Sciences Research (T Hoskin MS), Mayo Clinic, Rochester, MN, USA; Department of Pathology and Translational Molecular Pathology (R Gould BSc, Prof W F Symmans MBChB) and Department of Breast Medical Oncology (Prof V Valero MD), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA (Prof S B Edge MD); Department of Oncology (J E Abraham PhD, Prof C Caldas MD, Prof H Earl MBBS, S-J Sammut MD) and Department of Histopathology (E Provenzano MBBS), University of Cambridge, Cambridge, UK; Diagnostic Development Program, Ontario Institute for Cancer Research, Toronto, Canada (Prof J M S Bartlett PhD); Deanery of Molecular, Genetic and Population Health Sciences, Edinburgh Cancer Research Centre, Edinburgh, UK (Prof J M S Bartlett); Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada (Prof J M S Bartlett); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (Prof J Dunn PhD, L Hiller PhD); Department of Oncology (Prof L Hayward MRCP, Prof D Cameron MD, P Hall PhD) and Department of Pathology (J S Thomas MBBS, A Graham MBChB, L Mackintosh MBChB), Western General Hospital, Edinburgh, UK; Department of Pathology and Laboratory Medicine (Prof F Fan MD, Prof A K Godwin PhD) and Department of Medical Oncology (K Schwensen BS, Prof P Sharma MD), University of Kansas Medical Center, Kansas City, KS, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Prof A M DeMichele MD); Department of Pathology (K Cole MD) and Department of Medical Oncology (Prof L Pusztai MD), Yale University, New Haven, CT, USA
1,
Louise Hiller
Louise Hiller
1Department of Surgery (C Yau PhD, M Osdoit MD, M van der Noordaa MD, S Shad BS, J Wei BS, Prof L J Esserman MD), Department of Epidemiology and Biostatistics (Prof M-O Kim PhD), and Department of Laboratory Medicine (Prof L J van ‘t Veer PhD), University of California, San Francisco, San Francisco, CA, USA; Department of Surgery (M Osdoit, Prof F Reyal MD), Department of Tumor Biology (D de Croze MD, M Laé MD), and Department of Medical Oncology (A-S Hamy MD), Institut Curie, Paris, France; Department of Pathology, Université de Rouen Normandie, Rouen, France (M Laé); Department of Medical Oncology (Prof G S Sonke MD, T G Steenbruggen MD) and Department of Pathology (M van Seijen MD, Prof J Wesseling MD), Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Prof M Martín MD, M del Monte-Millán BSc, S López-Tarruella MD); Department of Surgery (Prof J C Boughey MD), Department of Oncology (Prof M P Goetz MD), and Department of Health Sciences Research (T Hoskin MS), Mayo Clinic, Rochester, MN, USA; Department of Pathology and Translational Molecular Pathology (R Gould BSc, Prof W F Symmans MBChB) and Department of Breast Medical Oncology (Prof V Valero MD), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA (Prof S B Edge MD); Department of Oncology (J E Abraham PhD, Prof C Caldas MD, Prof H Earl MBBS, S-J Sammut MD) and Department of Histopathology (E Provenzano MBBS), University of Cambridge, Cambridge, UK; Diagnostic Development Program, Ontario Institute for Cancer Research, Toronto, Canada (Prof J M S Bartlett PhD); Deanery of Molecular, Genetic and Population Health Sciences, Edinburgh Cancer Research Centre, Edinburgh, UK (Prof J M S Bartlett); Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada (Prof J M S Bartlett); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (Prof J Dunn PhD, L Hiller PhD); Department of Oncology (Prof L Hayward MRCP, Prof D Cameron MD, P Hall PhD) and Department of Pathology (J S Thomas MBBS, A Graham MBChB, L Mackintosh MBChB), Western General Hospital, Edinburgh, UK; Department of Pathology and Laboratory Medicine (Prof F Fan MD, Prof A K Godwin PhD) and Department of Medical Oncology (K Schwensen BS, Prof P Sharma MD), University of Kansas Medical Center, Kansas City, KS, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Prof A M DeMichele MD); Department of Pathology (K Cole MD) and Department of Medical Oncology (Prof L Pusztai MD), Yale University, New Haven, CT, USA
1,
Elena Provenzano
Elena Provenzano
1Department of Surgery (C Yau PhD, M Osdoit MD, M van der Noordaa MD, S Shad BS, J Wei BS, Prof L J Esserman MD), Department of Epidemiology and Biostatistics (Prof M-O Kim PhD), and Department of Laboratory Medicine (Prof L J van ‘t Veer PhD), University of California, San Francisco, San Francisco, CA, USA; Department of Surgery (M Osdoit, Prof F Reyal MD), Department of Tumor Biology (D de Croze MD, M Laé MD), and Department of Medical Oncology (A-S Hamy MD), Institut Curie, Paris, France; Department of Pathology, Université de Rouen Normandie, Rouen, France (M Laé); Department of Medical Oncology (Prof G S Sonke MD, T G Steenbruggen MD) and Department of Pathology (M van Seijen MD, Prof J Wesseling MD), Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Prof M Martín MD, M del Monte-Millán BSc, S López-Tarruella MD); Department of Surgery (Prof J C Boughey MD), Department of Oncology (Prof M P Goetz MD), and Department of Health Sciences Research (T Hoskin MS), Mayo Clinic, Rochester, MN, USA; Department of Pathology and Translational Molecular Pathology (R Gould BSc, Prof W F Symmans MBChB) and Department of Breast Medical Oncology (Prof V Valero MD), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA (Prof S B Edge MD); Department of Oncology (J E Abraham PhD, Prof C Caldas MD, Prof H Earl MBBS, S-J Sammut MD) and Department of Histopathology (E Provenzano MBBS), University of Cambridge, Cambridge, UK; Diagnostic Development Program, Ontario Institute for Cancer Research, Toronto, Canada (Prof J M S Bartlett PhD); Deanery of Molecular, Genetic and Population Health Sciences, Edinburgh Cancer Research Centre, Edinburgh, UK (Prof J M S Bartlett); Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada (Prof J M S Bartlett); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (Prof J Dunn PhD, L Hiller PhD); Department of Oncology (Prof L Hayward MRCP, Prof D Cameron MD, P Hall PhD) and Department of Pathology (J S Thomas MBBS, A Graham MBChB, L Mackintosh MBChB), Western General Hospital, Edinburgh, UK; Department of Pathology and Laboratory Medicine (Prof F Fan MD, Prof A K Godwin PhD) and Department of Medical Oncology (K Schwensen BS, Prof P Sharma MD), University of Kansas Medical Center, Kansas City, KS, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Prof A M DeMichele MD); Department of Pathology (K Cole MD) and Department of Medical Oncology (Prof L Pusztai MD), Yale University, New Haven, CT, USA
1,
Stephen-John Sammut
Stephen-John Sammut
1Department of Surgery (C Yau PhD, M Osdoit MD, M van der Noordaa MD, S Shad BS, J Wei BS, Prof L J Esserman MD), Department of Epidemiology and Biostatistics (Prof M-O Kim PhD), and Department of Laboratory Medicine (Prof L J van ‘t Veer PhD), University of California, San Francisco, San Francisco, CA, USA; Department of Surgery (M Osdoit, Prof F Reyal MD), Department of Tumor Biology (D de Croze MD, M Laé MD), and Department of Medical Oncology (A-S Hamy MD), Institut Curie, Paris, France; Department of Pathology, Université de Rouen Normandie, Rouen, France (M Laé); Department of Medical Oncology (Prof G S Sonke MD, T G Steenbruggen MD) and Department of Pathology (M van Seijen MD, Prof J Wesseling MD), Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Prof M Martín MD, M del Monte-Millán BSc, S López-Tarruella MD); Department of Surgery (Prof J C Boughey MD), Department of Oncology (Prof M P Goetz MD), and Department of Health Sciences Research (T Hoskin MS), Mayo Clinic, Rochester, MN, USA; Department of Pathology and Translational Molecular Pathology (R Gould BSc, Prof W F Symmans MBChB) and Department of Breast Medical Oncology (Prof V Valero MD), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA (Prof S B Edge MD); Department of Oncology (J E Abraham PhD, Prof C Caldas MD, Prof H Earl MBBS, S-J Sammut MD) and Department of Histopathology (E Provenzano MBBS), University of Cambridge, Cambridge, UK; Diagnostic Development Program, Ontario Institute for Cancer Research, Toronto, Canada (Prof J M S Bartlett PhD); Deanery of Molecular, Genetic and Population Health Sciences, Edinburgh Cancer Research Centre, Edinburgh, UK (Prof J M S Bartlett); Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada (Prof J M S Bartlett); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (Prof J Dunn PhD, L Hiller PhD); Department of Oncology (Prof L Hayward MRCP, Prof D Cameron MD, P Hall PhD) and Department of Pathology (J S Thomas MBBS, A Graham MBChB, L Mackintosh MBChB), Western General Hospital, Edinburgh, UK; Department of Pathology and Laboratory Medicine (Prof F Fan MD, Prof A K Godwin PhD) and Department of Medical Oncology (K Schwensen BS, Prof P Sharma MD), University of Kansas Medical Center, Kansas City, KS, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Prof A M DeMichele MD); Department of Pathology (K Cole MD) and Department of Medical Oncology (Prof L Pusztai MD), Yale University, New Haven, CT, USA
1,
Jeremy S Thomas
Jeremy S Thomas
1Department of Surgery (C Yau PhD, M Osdoit MD, M van der Noordaa MD, S Shad BS, J Wei BS, Prof L J Esserman MD), Department of Epidemiology and Biostatistics (Prof M-O Kim PhD), and Department of Laboratory Medicine (Prof L J van ‘t Veer PhD), University of California, San Francisco, San Francisco, CA, USA; Department of Surgery (M Osdoit, Prof F Reyal MD), Department of Tumor Biology (D de Croze MD, M Laé MD), and Department of Medical Oncology (A-S Hamy MD), Institut Curie, Paris, France; Department of Pathology, Université de Rouen Normandie, Rouen, France (M Laé); Department of Medical Oncology (Prof G S Sonke MD, T G Steenbruggen MD) and Department of Pathology (M van Seijen MD, Prof J Wesseling MD), Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Prof M Martín MD, M del Monte-Millán BSc, S López-Tarruella MD); Department of Surgery (Prof J C Boughey MD), Department of Oncology (Prof M P Goetz MD), and Department of Health Sciences Research (T Hoskin MS), Mayo Clinic, Rochester, MN, USA; Department of Pathology and Translational Molecular Pathology (R Gould BSc, Prof W F Symmans MBChB) and Department of Breast Medical Oncology (Prof V Valero MD), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA (Prof S B Edge MD); Department of Oncology (J E Abraham PhD, Prof C Caldas MD, Prof H Earl MBBS, S-J Sammut MD) and Department of Histopathology (E Provenzano MBBS), University of Cambridge, Cambridge, UK; Diagnostic Development Program, Ontario Institute for Cancer Research, Toronto, Canada (Prof J M S Bartlett PhD); Deanery of Molecular, Genetic and Population Health Sciences, Edinburgh Cancer Research Centre, Edinburgh, UK (Prof J M S Bartlett); Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada (Prof J M S Bartlett); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (Prof J Dunn PhD, L Hiller PhD); Department of Oncology (Prof L Hayward MRCP, Prof D Cameron MD, P Hall PhD) and Department of Pathology (J S Thomas MBBS, A Graham MBChB, L Mackintosh MBChB), Western General Hospital, Edinburgh, UK; Department of Pathology and Laboratory Medicine (Prof F Fan MD, Prof A K Godwin PhD) and Department of Medical Oncology (K Schwensen BS, Prof P Sharma MD), University of Kansas Medical Center, Kansas City, KS, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Prof A M DeMichele MD); Department of Pathology (K Cole MD) and Department of Medical Oncology (Prof L Pusztai MD), Yale University, New Haven, CT, USA
1,
David Cameron
David Cameron
1Department of Surgery (C Yau PhD, M Osdoit MD, M van der Noordaa MD, S Shad BS, J Wei BS, Prof L J Esserman MD), Department of Epidemiology and Biostatistics (Prof M-O Kim PhD), and Department of Laboratory Medicine (Prof L J van ‘t Veer PhD), University of California, San Francisco, San Francisco, CA, USA; Department of Surgery (M Osdoit, Prof F Reyal MD), Department of Tumor Biology (D de Croze MD, M Laé MD), and Department of Medical Oncology (A-S Hamy MD), Institut Curie, Paris, France; Department of Pathology, Université de Rouen Normandie, Rouen, France (M Laé); Department of Medical Oncology (Prof G S Sonke MD, T G Steenbruggen MD) and Department of Pathology (M van Seijen MD, Prof J Wesseling MD), Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Prof M Martín MD, M del Monte-Millán BSc, S López-Tarruella MD); Department of Surgery (Prof J C Boughey MD), Department of Oncology (Prof M P Goetz MD), and Department of Health Sciences Research (T Hoskin MS), Mayo Clinic, Rochester, MN, USA; Department of Pathology and Translational Molecular Pathology (R Gould BSc, Prof W F Symmans MBChB) and Department of Breast Medical Oncology (Prof V Valero MD), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA (Prof S B Edge MD); Department of Oncology (J E Abraham PhD, Prof C Caldas MD, Prof H Earl MBBS, S-J Sammut MD) and Department of Histopathology (E Provenzano MBBS), University of Cambridge, Cambridge, UK; Diagnostic Development Program, Ontario Institute for Cancer Research, Toronto, Canada (Prof J M S Bartlett PhD); Deanery of Molecular, Genetic and Population Health Sciences, Edinburgh Cancer Research Centre, Edinburgh, UK (Prof J M S Bartlett); Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada (Prof J M S Bartlett); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (Prof J Dunn PhD, L Hiller PhD); Department of Oncology (Prof L Hayward MRCP, Prof D Cameron MD, P Hall PhD) and Department of Pathology (J S Thomas MBBS, A Graham MBChB, L Mackintosh MBChB), Western General Hospital, Edinburgh, UK; Department of Pathology and Laboratory Medicine (Prof F Fan MD, Prof A K Godwin PhD) and Department of Medical Oncology (K Schwensen BS, Prof P Sharma MD), University of Kansas Medical Center, Kansas City, KS, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Prof A M DeMichele MD); Department of Pathology (K Cole MD) and Department of Medical Oncology (Prof L Pusztai MD), Yale University, New Haven, CT, USA
1,
Ashley Graham
Ashley Graham
1Department of Surgery (C Yau PhD, M Osdoit MD, M van der Noordaa MD, S Shad BS, J Wei BS, Prof L J Esserman MD), Department of Epidemiology and Biostatistics (Prof M-O Kim PhD), and Department of Laboratory Medicine (Prof L J van ‘t Veer PhD), University of California, San Francisco, San Francisco, CA, USA; Department of Surgery (M Osdoit, Prof F Reyal MD), Department of Tumor Biology (D de Croze MD, M Laé MD), and Department of Medical Oncology (A-S Hamy MD), Institut Curie, Paris, France; Department of Pathology, Université de Rouen Normandie, Rouen, France (M Laé); Department of Medical Oncology (Prof G S Sonke MD, T G Steenbruggen MD) and Department of Pathology (M van Seijen MD, Prof J Wesseling MD), Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Prof M Martín MD, M del Monte-Millán BSc, S López-Tarruella MD); Department of Surgery (Prof J C Boughey MD), Department of Oncology (Prof M P Goetz MD), and Department of Health Sciences Research (T Hoskin MS), Mayo Clinic, Rochester, MN, USA; Department of Pathology and Translational Molecular Pathology (R Gould BSc, Prof W F Symmans MBChB) and Department of Breast Medical Oncology (Prof V Valero MD), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA (Prof S B Edge MD); Department of Oncology (J E Abraham PhD, Prof C Caldas MD, Prof H Earl MBBS, S-J Sammut MD) and Department of Histopathology (E Provenzano MBBS), University of Cambridge, Cambridge, UK; Diagnostic Development Program, Ontario Institute for Cancer Research, Toronto, Canada (Prof J M S Bartlett PhD); Deanery of Molecular, Genetic and Population Health Sciences, Edinburgh Cancer Research Centre, Edinburgh, UK (Prof J M S Bartlett); Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada (Prof J M S Bartlett); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (Prof J Dunn PhD, L Hiller PhD); Department of Oncology (Prof L Hayward MRCP, Prof D Cameron MD, P Hall PhD) and Department of Pathology (J S Thomas MBBS, A Graham MBChB, L Mackintosh MBChB), Western General Hospital, Edinburgh, UK; Department of Pathology and Laboratory Medicine (Prof F Fan MD, Prof A K Godwin PhD) and Department of Medical Oncology (K Schwensen BS, Prof P Sharma MD), University of Kansas Medical Center, Kansas City, KS, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Prof A M DeMichele MD); Department of Pathology (K Cole MD) and Department of Medical Oncology (Prof L Pusztai MD), Yale University, New Haven, CT, USA
1,
Peter Hall
Peter Hall
1Department of Surgery (C Yau PhD, M Osdoit MD, M van der Noordaa MD, S Shad BS, J Wei BS, Prof L J Esserman MD), Department of Epidemiology and Biostatistics (Prof M-O Kim PhD), and Department of Laboratory Medicine (Prof L J van ‘t Veer PhD), University of California, San Francisco, San Francisco, CA, USA; Department of Surgery (M Osdoit, Prof F Reyal MD), Department of Tumor Biology (D de Croze MD, M Laé MD), and Department of Medical Oncology (A-S Hamy MD), Institut Curie, Paris, France; Department of Pathology, Université de Rouen Normandie, Rouen, France (M Laé); Department of Medical Oncology (Prof G S Sonke MD, T G Steenbruggen MD) and Department of Pathology (M van Seijen MD, Prof J Wesseling MD), Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Prof M Martín MD, M del Monte-Millán BSc, S López-Tarruella MD); Department of Surgery (Prof J C Boughey MD), Department of Oncology (Prof M P Goetz MD), and Department of Health Sciences Research (T Hoskin MS), Mayo Clinic, Rochester, MN, USA; Department of Pathology and Translational Molecular Pathology (R Gould BSc, Prof W F Symmans MBChB) and Department of Breast Medical Oncology (Prof V Valero MD), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA (Prof S B Edge MD); Department of Oncology (J E Abraham PhD, Prof C Caldas MD, Prof H Earl MBBS, S-J Sammut MD) and Department of Histopathology (E Provenzano MBBS), University of Cambridge, Cambridge, UK; Diagnostic Development Program, Ontario Institute for Cancer Research, Toronto, Canada (Prof J M S Bartlett PhD); Deanery of Molecular, Genetic and Population Health Sciences, Edinburgh Cancer Research Centre, Edinburgh, UK (Prof J M S Bartlett); Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada (Prof J M S Bartlett); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (Prof J Dunn PhD, L Hiller PhD); Department of Oncology (Prof L Hayward MRCP, Prof D Cameron MD, P Hall PhD) and Department of Pathology (J S Thomas MBBS, A Graham MBChB, L Mackintosh MBChB), Western General Hospital, Edinburgh, UK; Department of Pathology and Laboratory Medicine (Prof F Fan MD, Prof A K Godwin PhD) and Department of Medical Oncology (K Schwensen BS, Prof P Sharma MD), University of Kansas Medical Center, Kansas City, KS, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Prof A M DeMichele MD); Department of Pathology (K Cole MD) and Department of Medical Oncology (Prof L Pusztai MD), Yale University, New Haven, CT, USA
1,
Lorna Mackintosh
Lorna Mackintosh
1Department of Surgery (C Yau PhD, M Osdoit MD, M van der Noordaa MD, S Shad BS, J Wei BS, Prof L J Esserman MD), Department of Epidemiology and Biostatistics (Prof M-O Kim PhD), and Department of Laboratory Medicine (Prof L J van ‘t Veer PhD), University of California, San Francisco, San Francisco, CA, USA; Department of Surgery (M Osdoit, Prof F Reyal MD), Department of Tumor Biology (D de Croze MD, M Laé MD), and Department of Medical Oncology (A-S Hamy MD), Institut Curie, Paris, France; Department of Pathology, Université de Rouen Normandie, Rouen, France (M Laé); Department of Medical Oncology (Prof G S Sonke MD, T G Steenbruggen MD) and Department of Pathology (M van Seijen MD, Prof J Wesseling MD), Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Prof M Martín MD, M del Monte-Millán BSc, S López-Tarruella MD); Department of Surgery (Prof J C Boughey MD), Department of Oncology (Prof M P Goetz MD), and Department of Health Sciences Research (T Hoskin MS), Mayo Clinic, Rochester, MN, USA; Department of Pathology and Translational Molecular Pathology (R Gould BSc, Prof W F Symmans MBChB) and Department of Breast Medical Oncology (Prof V Valero MD), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA (Prof S B Edge MD); Department of Oncology (J E Abraham PhD, Prof C Caldas MD, Prof H Earl MBBS, S-J Sammut MD) and Department of Histopathology (E Provenzano MBBS), University of Cambridge, Cambridge, UK; Diagnostic Development Program, Ontario Institute for Cancer Research, Toronto, Canada (Prof J M S Bartlett PhD); Deanery of Molecular, Genetic and Population Health Sciences, Edinburgh Cancer Research Centre, Edinburgh, UK (Prof J M S Bartlett); Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada (Prof J M S Bartlett); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (Prof J Dunn PhD, L Hiller PhD); Department of Oncology (Prof L Hayward MRCP, Prof D Cameron MD, P Hall PhD) and Department of Pathology (J S Thomas MBBS, A Graham MBChB, L Mackintosh MBChB), Western General Hospital, Edinburgh, UK; Department of Pathology and Laboratory Medicine (Prof F Fan MD, Prof A K Godwin PhD) and Department of Medical Oncology (K Schwensen BS, Prof P Sharma MD), University of Kansas Medical Center, Kansas City, KS, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Prof A M DeMichele MD); Department of Pathology (K Cole MD) and Department of Medical Oncology (Prof L Pusztai MD), Yale University, New Haven, CT, USA
1,
Fang Fan
Fang Fan
1Department of Surgery (C Yau PhD, M Osdoit MD, M van der Noordaa MD, S Shad BS, J Wei BS, Prof L J Esserman MD), Department of Epidemiology and Biostatistics (Prof M-O Kim PhD), and Department of Laboratory Medicine (Prof L J van ‘t Veer PhD), University of California, San Francisco, San Francisco, CA, USA; Department of Surgery (M Osdoit, Prof F Reyal MD), Department of Tumor Biology (D de Croze MD, M Laé MD), and Department of Medical Oncology (A-S Hamy MD), Institut Curie, Paris, France; Department of Pathology, Université de Rouen Normandie, Rouen, France (M Laé); Department of Medical Oncology (Prof G S Sonke MD, T G Steenbruggen MD) and Department of Pathology (M van Seijen MD, Prof J Wesseling MD), Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Prof M Martín MD, M del Monte-Millán BSc, S López-Tarruella MD); Department of Surgery (Prof J C Boughey MD), Department of Oncology (Prof M P Goetz MD), and Department of Health Sciences Research (T Hoskin MS), Mayo Clinic, Rochester, MN, USA; Department of Pathology and Translational Molecular Pathology (R Gould BSc, Prof W F Symmans MBChB) and Department of Breast Medical Oncology (Prof V Valero MD), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA (Prof S B Edge MD); Department of Oncology (J E Abraham PhD, Prof C Caldas MD, Prof H Earl MBBS, S-J Sammut MD) and Department of Histopathology (E Provenzano MBBS), University of Cambridge, Cambridge, UK; Diagnostic Development Program, Ontario Institute for Cancer Research, Toronto, Canada (Prof J M S Bartlett PhD); Deanery of Molecular, Genetic and Population Health Sciences, Edinburgh Cancer Research Centre, Edinburgh, UK (Prof J M S Bartlett); Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada (Prof J M S Bartlett); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (Prof J Dunn PhD, L Hiller PhD); Department of Oncology (Prof L Hayward MRCP, Prof D Cameron MD, P Hall PhD) and Department of Pathology (J S Thomas MBBS, A Graham MBChB, L Mackintosh MBChB), Western General Hospital, Edinburgh, UK; Department of Pathology and Laboratory Medicine (Prof F Fan MD, Prof A K Godwin PhD) and Department of Medical Oncology (K Schwensen BS, Prof P Sharma MD), University of Kansas Medical Center, Kansas City, KS, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Prof A M DeMichele MD); Department of Pathology (K Cole MD) and Department of Medical Oncology (Prof L Pusztai MD), Yale University, New Haven, CT, USA
1,
Andrew K Godwin
Andrew K Godwin
1Department of Surgery (C Yau PhD, M Osdoit MD, M van der Noordaa MD, S Shad BS, J Wei BS, Prof L J Esserman MD), Department of Epidemiology and Biostatistics (Prof M-O Kim PhD), and Department of Laboratory Medicine (Prof L J van ‘t Veer PhD), University of California, San Francisco, San Francisco, CA, USA; Department of Surgery (M Osdoit, Prof F Reyal MD), Department of Tumor Biology (D de Croze MD, M Laé MD), and Department of Medical Oncology (A-S Hamy MD), Institut Curie, Paris, France; Department of Pathology, Université de Rouen Normandie, Rouen, France (M Laé); Department of Medical Oncology (Prof G S Sonke MD, T G Steenbruggen MD) and Department of Pathology (M van Seijen MD, Prof J Wesseling MD), Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Prof M Martín MD, M del Monte-Millán BSc, S López-Tarruella MD); Department of Surgery (Prof J C Boughey MD), Department of Oncology (Prof M P Goetz MD), and Department of Health Sciences Research (T Hoskin MS), Mayo Clinic, Rochester, MN, USA; Department of Pathology and Translational Molecular Pathology (R Gould BSc, Prof W F Symmans MBChB) and Department of Breast Medical Oncology (Prof V Valero MD), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA (Prof S B Edge MD); Department of Oncology (J E Abraham PhD, Prof C Caldas MD, Prof H Earl MBBS, S-J Sammut MD) and Department of Histopathology (E Provenzano MBBS), University of Cambridge, Cambridge, UK; Diagnostic Development Program, Ontario Institute for Cancer Research, Toronto, Canada (Prof J M S Bartlett PhD); Deanery of Molecular, Genetic and Population Health Sciences, Edinburgh Cancer Research Centre, Edinburgh, UK (Prof J M S Bartlett); Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada (Prof J M S Bartlett); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (Prof J Dunn PhD, L Hiller PhD); Department of Oncology (Prof L Hayward MRCP, Prof D Cameron MD, P Hall PhD) and Department of Pathology (J S Thomas MBBS, A Graham MBChB, L Mackintosh MBChB), Western General Hospital, Edinburgh, UK; Department of Pathology and Laboratory Medicine (Prof F Fan MD, Prof A K Godwin PhD) and Department of Medical Oncology (K Schwensen BS, Prof P Sharma MD), University of Kansas Medical Center, Kansas City, KS, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Prof A M DeMichele MD); Department of Pathology (K Cole MD) and Department of Medical Oncology (Prof L Pusztai MD), Yale University, New Haven, CT, USA
1,
Kelsey Schwensen
Kelsey Schwensen
1Department of Surgery (C Yau PhD, M Osdoit MD, M van der Noordaa MD, S Shad BS, J Wei BS, Prof L J Esserman MD), Department of Epidemiology and Biostatistics (Prof M-O Kim PhD), and Department of Laboratory Medicine (Prof L J van ‘t Veer PhD), University of California, San Francisco, San Francisco, CA, USA; Department of Surgery (M Osdoit, Prof F Reyal MD), Department of Tumor Biology (D de Croze MD, M Laé MD), and Department of Medical Oncology (A-S Hamy MD), Institut Curie, Paris, France; Department of Pathology, Université de Rouen Normandie, Rouen, France (M Laé); Department of Medical Oncology (Prof G S Sonke MD, T G Steenbruggen MD) and Department of Pathology (M van Seijen MD, Prof J Wesseling MD), Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Prof M Martín MD, M del Monte-Millán BSc, S López-Tarruella MD); Department of Surgery (Prof J C Boughey MD), Department of Oncology (Prof M P Goetz MD), and Department of Health Sciences Research (T Hoskin MS), Mayo Clinic, Rochester, MN, USA; Department of Pathology and Translational Molecular Pathology (R Gould BSc, Prof W F Symmans MBChB) and Department of Breast Medical Oncology (Prof V Valero MD), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA (Prof S B Edge MD); Department of Oncology (J E Abraham PhD, Prof C Caldas MD, Prof H Earl MBBS, S-J Sammut MD) and Department of Histopathology (E Provenzano MBBS), University of Cambridge, Cambridge, UK; Diagnostic Development Program, Ontario Institute for Cancer Research, Toronto, Canada (Prof J M S Bartlett PhD); Deanery of Molecular, Genetic and Population Health Sciences, Edinburgh Cancer Research Centre, Edinburgh, UK (Prof J M S Bartlett); Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada (Prof J M S Bartlett); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (Prof J Dunn PhD, L Hiller PhD); Department of Oncology (Prof L Hayward MRCP, Prof D Cameron MD, P Hall PhD) and Department of Pathology (J S Thomas MBBS, A Graham MBChB, L Mackintosh MBChB), Western General Hospital, Edinburgh, UK; Department of Pathology and Laboratory Medicine (Prof F Fan MD, Prof A K Godwin PhD) and Department of Medical Oncology (K Schwensen BS, Prof P Sharma MD), University of Kansas Medical Center, Kansas City, KS, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Prof A M DeMichele MD); Department of Pathology (K Cole MD) and Department of Medical Oncology (Prof L Pusztai MD), Yale University, New Haven, CT, USA
1,
Priyanka Sharma
Priyanka Sharma
1Department of Surgery (C Yau PhD, M Osdoit MD, M van der Noordaa MD, S Shad BS, J Wei BS, Prof L J Esserman MD), Department of Epidemiology and Biostatistics (Prof M-O Kim PhD), and Department of Laboratory Medicine (Prof L J van ‘t Veer PhD), University of California, San Francisco, San Francisco, CA, USA; Department of Surgery (M Osdoit, Prof F Reyal MD), Department of Tumor Biology (D de Croze MD, M Laé MD), and Department of Medical Oncology (A-S Hamy MD), Institut Curie, Paris, France; Department of Pathology, Université de Rouen Normandie, Rouen, France (M Laé); Department of Medical Oncology (Prof G S Sonke MD, T G Steenbruggen MD) and Department of Pathology (M van Seijen MD, Prof J Wesseling MD), Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Prof M Martín MD, M del Monte-Millán BSc, S López-Tarruella MD); Department of Surgery (Prof J C Boughey MD), Department of Oncology (Prof M P Goetz MD), and Department of Health Sciences Research (T Hoskin MS), Mayo Clinic, Rochester, MN, USA; Department of Pathology and Translational Molecular Pathology (R Gould BSc, Prof W F Symmans MBChB) and Department of Breast Medical Oncology (Prof V Valero MD), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA (Prof S B Edge MD); Department of Oncology (J E Abraham PhD, Prof C Caldas MD, Prof H Earl MBBS, S-J Sammut MD) and Department of Histopathology (E Provenzano MBBS), University of Cambridge, Cambridge, UK; Diagnostic Development Program, Ontario Institute for Cancer Research, Toronto, Canada (Prof J M S Bartlett PhD); Deanery of Molecular, Genetic and Population Health Sciences, Edinburgh Cancer Research Centre, Edinburgh, UK (Prof J M S Bartlett); Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada (Prof J M S Bartlett); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (Prof J Dunn PhD, L Hiller PhD); Department of Oncology (Prof L Hayward MRCP, Prof D Cameron MD, P Hall PhD) and Department of Pathology (J S Thomas MBBS, A Graham MBChB, L Mackintosh MBChB), Western General Hospital, Edinburgh, UK; Department of Pathology and Laboratory Medicine (Prof F Fan MD, Prof A K Godwin PhD) and Department of Medical Oncology (K Schwensen BS, Prof P Sharma MD), University of Kansas Medical Center, Kansas City, KS, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Prof A M DeMichele MD); Department of Pathology (K Cole MD) and Department of Medical Oncology (Prof L Pusztai MD), Yale University, New Haven, CT, USA
1,
Angela M DeMichele
Angela M DeMichele
1Department of Surgery (C Yau PhD, M Osdoit MD, M van der Noordaa MD, S Shad BS, J Wei BS, Prof L J Esserman MD), Department of Epidemiology and Biostatistics (Prof M-O Kim PhD), and Department of Laboratory Medicine (Prof L J van ‘t Veer PhD), University of California, San Francisco, San Francisco, CA, USA; Department of Surgery (M Osdoit, Prof F Reyal MD), Department of Tumor Biology (D de Croze MD, M Laé MD), and Department of Medical Oncology (A-S Hamy MD), Institut Curie, Paris, France; Department of Pathology, Université de Rouen Normandie, Rouen, France (M Laé); Department of Medical Oncology (Prof G S Sonke MD, T G Steenbruggen MD) and Department of Pathology (M van Seijen MD, Prof J Wesseling MD), Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Prof M Martín MD, M del Monte-Millán BSc, S López-Tarruella MD); Department of Surgery (Prof J C Boughey MD), Department of Oncology (Prof M P Goetz MD), and Department of Health Sciences Research (T Hoskin MS), Mayo Clinic, Rochester, MN, USA; Department of Pathology and Translational Molecular Pathology (R Gould BSc, Prof W F Symmans MBChB) and Department of Breast Medical Oncology (Prof V Valero MD), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA (Prof S B Edge MD); Department of Oncology (J E Abraham PhD, Prof C Caldas MD, Prof H Earl MBBS, S-J Sammut MD) and Department of Histopathology (E Provenzano MBBS), University of Cambridge, Cambridge, UK; Diagnostic Development Program, Ontario Institute for Cancer Research, Toronto, Canada (Prof J M S Bartlett PhD); Deanery of Molecular, Genetic and Population Health Sciences, Edinburgh Cancer Research Centre, Edinburgh, UK (Prof J M S Bartlett); Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada (Prof J M S Bartlett); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (Prof J Dunn PhD, L Hiller PhD); Department of Oncology (Prof L Hayward MRCP, Prof D Cameron MD, P Hall PhD) and Department of Pathology (J S Thomas MBBS, A Graham MBChB, L Mackintosh MBChB), Western General Hospital, Edinburgh, UK; Department of Pathology and Laboratory Medicine (Prof F Fan MD, Prof A K Godwin PhD) and Department of Medical Oncology (K Schwensen BS, Prof P Sharma MD), University of Kansas Medical Center, Kansas City, KS, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Prof A M DeMichele MD); Department of Pathology (K Cole MD) and Department of Medical Oncology (Prof L Pusztai MD), Yale University, New Haven, CT, USA
1,
Kimberly Cole
Kimberly Cole
1Department of Surgery (C Yau PhD, M Osdoit MD, M van der Noordaa MD, S Shad BS, J Wei BS, Prof L J Esserman MD), Department of Epidemiology and Biostatistics (Prof M-O Kim PhD), and Department of Laboratory Medicine (Prof L J van ‘t Veer PhD), University of California, San Francisco, San Francisco, CA, USA; Department of Surgery (M Osdoit, Prof F Reyal MD), Department of Tumor Biology (D de Croze MD, M Laé MD), and Department of Medical Oncology (A-S Hamy MD), Institut Curie, Paris, France; Department of Pathology, Université de Rouen Normandie, Rouen, France (M Laé); Department of Medical Oncology (Prof G S Sonke MD, T G Steenbruggen MD) and Department of Pathology (M van Seijen MD, Prof J Wesseling MD), Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Prof M Martín MD, M del Monte-Millán BSc, S López-Tarruella MD); Department of Surgery (Prof J C Boughey MD), Department of Oncology (Prof M P Goetz MD), and Department of Health Sciences Research (T Hoskin MS), Mayo Clinic, Rochester, MN, USA; Department of Pathology and Translational Molecular Pathology (R Gould BSc, Prof W F Symmans MBChB) and Department of Breast Medical Oncology (Prof V Valero MD), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA (Prof S B Edge MD); Department of Oncology (J E Abraham PhD, Prof C Caldas MD, Prof H Earl MBBS, S-J Sammut MD) and Department of Histopathology (E Provenzano MBBS), University of Cambridge, Cambridge, UK; Diagnostic Development Program, Ontario Institute for Cancer Research, Toronto, Canada (Prof J M S Bartlett PhD); Deanery of Molecular, Genetic and Population Health Sciences, Edinburgh Cancer Research Centre, Edinburgh, UK (Prof J M S Bartlett); Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada (Prof J M S Bartlett); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (Prof J Dunn PhD, L Hiller PhD); Department of Oncology (Prof L Hayward MRCP, Prof D Cameron MD, P Hall PhD) and Department of Pathology (J S Thomas MBBS, A Graham MBChB, L Mackintosh MBChB), Western General Hospital, Edinburgh, UK; Department of Pathology and Laboratory Medicine (Prof F Fan MD, Prof A K Godwin PhD) and Department of Medical Oncology (K Schwensen BS, Prof P Sharma MD), University of Kansas Medical Center, Kansas City, KS, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Prof A M DeMichele MD); Department of Pathology (K Cole MD) and Department of Medical Oncology (Prof L Pusztai MD), Yale University, New Haven, CT, USA
1,
Lajos Pusztai
Lajos Pusztai
1Department of Surgery (C Yau PhD, M Osdoit MD, M van der Noordaa MD, S Shad BS, J Wei BS, Prof L J Esserman MD), Department of Epidemiology and Biostatistics (Prof M-O Kim PhD), and Department of Laboratory Medicine (Prof L J van ‘t Veer PhD), University of California, San Francisco, San Francisco, CA, USA; Department of Surgery (M Osdoit, Prof F Reyal MD), Department of Tumor Biology (D de Croze MD, M Laé MD), and Department of Medical Oncology (A-S Hamy MD), Institut Curie, Paris, France; Department of Pathology, Université de Rouen Normandie, Rouen, France (M Laé); Department of Medical Oncology (Prof G S Sonke MD, T G Steenbruggen MD) and Department of Pathology (M van Seijen MD, Prof J Wesseling MD), Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Prof M Martín MD, M del Monte-Millán BSc, S López-Tarruella MD); Department of Surgery (Prof J C Boughey MD), Department of Oncology (Prof M P Goetz MD), and Department of Health Sciences Research (T Hoskin MS), Mayo Clinic, Rochester, MN, USA; Department of Pathology and Translational Molecular Pathology (R Gould BSc, Prof W F Symmans MBChB) and Department of Breast Medical Oncology (Prof V Valero MD), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA (Prof S B Edge MD); Department of Oncology (J E Abraham PhD, Prof C Caldas MD, Prof H Earl MBBS, S-J Sammut MD) and Department of Histopathology (E Provenzano MBBS), University of Cambridge, Cambridge, UK; Diagnostic Development Program, Ontario Institute for Cancer Research, Toronto, Canada (Prof J M S Bartlett PhD); Deanery of Molecular, Genetic and Population Health Sciences, Edinburgh Cancer Research Centre, Edinburgh, UK (Prof J M S Bartlett); Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada (Prof J M S Bartlett); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (Prof J Dunn PhD, L Hiller PhD); Department of Oncology (Prof L Hayward MRCP, Prof D Cameron MD, P Hall PhD) and Department of Pathology (J S Thomas MBBS, A Graham MBChB, L Mackintosh MBChB), Western General Hospital, Edinburgh, UK; Department of Pathology and Laboratory Medicine (Prof F Fan MD, Prof A K Godwin PhD) and Department of Medical Oncology (K Schwensen BS, Prof P Sharma MD), University of Kansas Medical Center, Kansas City, KS, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Prof A M DeMichele MD); Department of Pathology (K Cole MD) and Department of Medical Oncology (Prof L Pusztai MD), Yale University, New Haven, CT, USA
1,
Mi-Ok Kim
Mi-Ok Kim
1Department of Surgery (C Yau PhD, M Osdoit MD, M van der Noordaa MD, S Shad BS, J Wei BS, Prof L J Esserman MD), Department of Epidemiology and Biostatistics (Prof M-O Kim PhD), and Department of Laboratory Medicine (Prof L J van ‘t Veer PhD), University of California, San Francisco, San Francisco, CA, USA; Department of Surgery (M Osdoit, Prof F Reyal MD), Department of Tumor Biology (D de Croze MD, M Laé MD), and Department of Medical Oncology (A-S Hamy MD), Institut Curie, Paris, France; Department of Pathology, Université de Rouen Normandie, Rouen, France (M Laé); Department of Medical Oncology (Prof G S Sonke MD, T G Steenbruggen MD) and Department of Pathology (M van Seijen MD, Prof J Wesseling MD), Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Prof M Martín MD, M del Monte-Millán BSc, S López-Tarruella MD); Department of Surgery (Prof J C Boughey MD), Department of Oncology (Prof M P Goetz MD), and Department of Health Sciences Research (T Hoskin MS), Mayo Clinic, Rochester, MN, USA; Department of Pathology and Translational Molecular Pathology (R Gould BSc, Prof W F Symmans MBChB) and Department of Breast Medical Oncology (Prof V Valero MD), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA (Prof S B Edge MD); Department of Oncology (J E Abraham PhD, Prof C Caldas MD, Prof H Earl MBBS, S-J Sammut MD) and Department of Histopathology (E Provenzano MBBS), University of Cambridge, Cambridge, UK; Diagnostic Development Program, Ontario Institute for Cancer Research, Toronto, Canada (Prof J M S Bartlett PhD); Deanery of Molecular, Genetic and Population Health Sciences, Edinburgh Cancer Research Centre, Edinburgh, UK (Prof J M S Bartlett); Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada (Prof J M S Bartlett); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (Prof J Dunn PhD, L Hiller PhD); Department of Oncology (Prof L Hayward MRCP, Prof D Cameron MD, P Hall PhD) and Department of Pathology (J S Thomas MBBS, A Graham MBChB, L Mackintosh MBChB), Western General Hospital, Edinburgh, UK; Department of Pathology and Laboratory Medicine (Prof F Fan MD, Prof A K Godwin PhD) and Department of Medical Oncology (K Schwensen BS, Prof P Sharma MD), University of Kansas Medical Center, Kansas City, KS, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Prof A M DeMichele MD); Department of Pathology (K Cole MD) and Department of Medical Oncology (Prof L Pusztai MD), Yale University, New Haven, CT, USA
1,
Laura J van ‘t Veer
Laura J van ‘t Veer
1Department of Surgery (C Yau PhD, M Osdoit MD, M van der Noordaa MD, S Shad BS, J Wei BS, Prof L J Esserman MD), Department of Epidemiology and Biostatistics (Prof M-O Kim PhD), and Department of Laboratory Medicine (Prof L J van ‘t Veer PhD), University of California, San Francisco, San Francisco, CA, USA; Department of Surgery (M Osdoit, Prof F Reyal MD), Department of Tumor Biology (D de Croze MD, M Laé MD), and Department of Medical Oncology (A-S Hamy MD), Institut Curie, Paris, France; Department of Pathology, Université de Rouen Normandie, Rouen, France (M Laé); Department of Medical Oncology (Prof G S Sonke MD, T G Steenbruggen MD) and Department of Pathology (M van Seijen MD, Prof J Wesseling MD), Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Prof M Martín MD, M del Monte-Millán BSc, S López-Tarruella MD); Department of Surgery (Prof J C Boughey MD), Department of Oncology (Prof M P Goetz MD), and Department of Health Sciences Research (T Hoskin MS), Mayo Clinic, Rochester, MN, USA; Department of Pathology and Translational Molecular Pathology (R Gould BSc, Prof W F Symmans MBChB) and Department of Breast Medical Oncology (Prof V Valero MD), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA (Prof S B Edge MD); Department of Oncology (J E Abraham PhD, Prof C Caldas MD, Prof H Earl MBBS, S-J Sammut MD) and Department of Histopathology (E Provenzano MBBS), University of Cambridge, Cambridge, UK; Diagnostic Development Program, Ontario Institute for Cancer Research, Toronto, Canada (Prof J M S Bartlett PhD); Deanery of Molecular, Genetic and Population Health Sciences, Edinburgh Cancer Research Centre, Edinburgh, UK (Prof J M S Bartlett); Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada (Prof J M S Bartlett); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (Prof J Dunn PhD, L Hiller PhD); Department of Oncology (Prof L Hayward MRCP, Prof D Cameron MD, P Hall PhD) and Department of Pathology (J S Thomas MBBS, A Graham MBChB, L Mackintosh MBChB), Western General Hospital, Edinburgh, UK; Department of Pathology and Laboratory Medicine (Prof F Fan MD, Prof A K Godwin PhD) and Department of Medical Oncology (K Schwensen BS, Prof P Sharma MD), University of Kansas Medical Center, Kansas City, KS, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Prof A M DeMichele MD); Department of Pathology (K Cole MD) and Department of Medical Oncology (Prof L Pusztai MD), Yale University, New Haven, CT, USA
1,
Laura J Esserman
Laura J Esserman
1Department of Surgery (C Yau PhD, M Osdoit MD, M van der Noordaa MD, S Shad BS, J Wei BS, Prof L J Esserman MD), Department of Epidemiology and Biostatistics (Prof M-O Kim PhD), and Department of Laboratory Medicine (Prof L J van ‘t Veer PhD), University of California, San Francisco, San Francisco, CA, USA; Department of Surgery (M Osdoit, Prof F Reyal MD), Department of Tumor Biology (D de Croze MD, M Laé MD), and Department of Medical Oncology (A-S Hamy MD), Institut Curie, Paris, France; Department of Pathology, Université de Rouen Normandie, Rouen, France (M Laé); Department of Medical Oncology (Prof G S Sonke MD, T G Steenbruggen MD) and Department of Pathology (M van Seijen MD, Prof J Wesseling MD), Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Prof M Martín MD, M del Monte-Millán BSc, S López-Tarruella MD); Department of Surgery (Prof J C Boughey MD), Department of Oncology (Prof M P Goetz MD), and Department of Health Sciences Research (T Hoskin MS), Mayo Clinic, Rochester, MN, USA; Department of Pathology and Translational Molecular Pathology (R Gould BSc, Prof W F Symmans MBChB) and Department of Breast Medical Oncology (Prof V Valero MD), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA (Prof S B Edge MD); Department of Oncology (J E Abraham PhD, Prof C Caldas MD, Prof H Earl MBBS, S-J Sammut MD) and Department of Histopathology (E Provenzano MBBS), University of Cambridge, Cambridge, UK; Diagnostic Development Program, Ontario Institute for Cancer Research, Toronto, Canada (Prof J M S Bartlett PhD); Deanery of Molecular, Genetic and Population Health Sciences, Edinburgh Cancer Research Centre, Edinburgh, UK (Prof J M S Bartlett); Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada (Prof J M S Bartlett); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (Prof J Dunn PhD, L Hiller PhD); Department of Oncology (Prof L Hayward MRCP, Prof D Cameron MD, P Hall PhD) and Department of Pathology (J S Thomas MBBS, A Graham MBChB, L Mackintosh MBChB), Western General Hospital, Edinburgh, UK; Department of Pathology and Laboratory Medicine (Prof F Fan MD, Prof A K Godwin PhD) and Department of Medical Oncology (K Schwensen BS, Prof P Sharma MD), University of Kansas Medical Center, Kansas City, KS, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Prof A M DeMichele MD); Department of Pathology (K Cole MD) and Department of Medical Oncology (Prof L Pusztai MD), Yale University, New Haven, CT, USA
1,
W Fraser Symmans
W Fraser Symmans
1Department of Surgery (C Yau PhD, M Osdoit MD, M van der Noordaa MD, S Shad BS, J Wei BS, Prof L J Esserman MD), Department of Epidemiology and Biostatistics (Prof M-O Kim PhD), and Department of Laboratory Medicine (Prof L J van ‘t Veer PhD), University of California, San Francisco, San Francisco, CA, USA; Department of Surgery (M Osdoit, Prof F Reyal MD), Department of Tumor Biology (D de Croze MD, M Laé MD), and Department of Medical Oncology (A-S Hamy MD), Institut Curie, Paris, France; Department of Pathology, Université de Rouen Normandie, Rouen, France (M Laé); Department of Medical Oncology (Prof G S Sonke MD, T G Steenbruggen MD) and Department of Pathology (M van Seijen MD, Prof J Wesseling MD), Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Prof M Martín MD, M del Monte-Millán BSc, S López-Tarruella MD); Department of Surgery (Prof J C Boughey MD), Department of Oncology (Prof M P Goetz MD), and Department of Health Sciences Research (T Hoskin MS), Mayo Clinic, Rochester, MN, USA; Department of Pathology and Translational Molecular Pathology (R Gould BSc, Prof W F Symmans MBChB) and Department of Breast Medical Oncology (Prof V Valero MD), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA (Prof S B Edge MD); Department of Oncology (J E Abraham PhD, Prof C Caldas MD, Prof H Earl MBBS, S-J Sammut MD) and Department of Histopathology (E Provenzano MBBS), University of Cambridge, Cambridge, UK; Diagnostic Development Program, Ontario Institute for Cancer Research, Toronto, Canada (Prof J M S Bartlett PhD); Deanery of Molecular, Genetic and Population Health Sciences, Edinburgh Cancer Research Centre, Edinburgh, UK (Prof J M S Bartlett); Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada (Prof J M S Bartlett); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (Prof J Dunn PhD, L Hiller PhD); Department of Oncology (Prof L Hayward MRCP, Prof D Cameron MD, P Hall PhD) and Department of Pathology (J S Thomas MBBS, A Graham MBChB, L Mackintosh MBChB), Western General Hospital, Edinburgh, UK; Department of Pathology and Laboratory Medicine (Prof F Fan MD, Prof A K Godwin PhD) and Department of Medical Oncology (K Schwensen BS, Prof P Sharma MD), University of Kansas Medical Center, Kansas City, KS, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Prof A M DeMichele MD); Department of Pathology (K Cole MD) and Department of Medical Oncology (Prof L Pusztai MD), Yale University, New Haven, CT, USA
1